WO2023008567A1 - Capsule shell composition and capsule obtained using same - Google Patents

Capsule shell composition and capsule obtained using same Download PDF

Info

Publication number
WO2023008567A1
WO2023008567A1 PCT/JP2022/029330 JP2022029330W WO2023008567A1 WO 2023008567 A1 WO2023008567 A1 WO 2023008567A1 JP 2022029330 W JP2022029330 W JP 2022029330W WO 2023008567 A1 WO2023008567 A1 WO 2023008567A1
Authority
WO
WIPO (PCT)
Prior art keywords
mass
capsule shell
content
capsule
starch
Prior art date
Application number
PCT/JP2022/029330
Other languages
French (fr)
Japanese (ja)
Inventor
真司 矢野
昌史 野津
雄斗 望月
明広 幡野
憲一 小山
崇典 小林
徹 風岡
広樹 小林
貴広 脇田
裕司 藤田
Original Assignee
三生医薬株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 三生医薬株式会社 filed Critical 三生医薬株式会社
Priority to JP2023538643A priority Critical patent/JPWO2023008567A1/ja
Publication of WO2023008567A1 publication Critical patent/WO2023008567A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate

Definitions

  • the present invention relates to a capsule shell composition and capsules using the same.
  • gelatin is suitably used for the capsule shell composition used in the production of capsule shells.
  • Gelatin exhibits suitable physical properties such as the viscosity and fluidity of the capsule shell composition, the strength of the formed capsule shell, heat-sealing properties, and resistance to cracking.
  • gelatin is mostly derived from animal collagen, and in recent years, from the viewpoint of religion, vegetarianism, allergies, mad cow disease, etc., there has been a demand for a capsule shell composition that uses a raw material that replaces gelatin as a main component. ing.
  • Patent Document 1 discloses a dry film composition suitable for soft capsules containing a mixture of iota carrageenan and modified starch, water, a plasticizer, and a buffer ( An invention relating to a capsule shell composition) is described.
  • Patent Document 1 describes that the capsule shell composition forms a film that is mechanically tough and has sufficient elasticity to stretch the film during filling (blow molding).
  • Patent Document 1 describes that a buffer (phosphate buffer) is added for the purpose of preventing destruction (decomposition) of carrageenan.
  • the capsule shell composition described in Patent Document 1 has high viscosity and is sometimes inferior in handleability. Therefore, there is a demand for a capsule shell composition that is easy to handle.
  • the present invention includes, for example, the following aspects.
  • a capsule shell composition comprising starches, iota carrageenan, and gums, The content of the iota carrageenan is 2% by mass or more with respect to 100% by mass of the capsule shell composition, A capsule shell composition, wherein the gum content is 0.3 to 14% by mass with respect to 100% by mass of the capsule shell composition.
  • the capsule shell composition according to [1] above which does not contain gelatin.
  • gum is one or more selected from the group consisting of gum arabic, guar gum, locust bean gum, gellan gum, xanthan gum, and tamarind gum. capsule shell composition.
  • the content ratio of starch to iota carrageenan (starch content (% by mass)/iota carrageenan content (% by mass)) is 1.2 to 10,
  • the content ratio of starches to gums (starch content (mass%) / gum content (mass%)) is 1 to 50, Any of the above [1] to [4], wherein the content ratio of iota carrageenan to gums (content of iota carrageenan (% by mass) / content of gums (% by mass)) is 0.5 to 15 2.
  • the capsule shell composition according to 1.
  • the starch content is 10 to 30% by mass with respect to 100% by mass of the capsule shell composition;
  • the starch contains at least one selected from the group consisting of natural starch and modified starch.
  • the content ratio of starch to iota carrageenan in the capsule shell (starch content (% by mass) / iota carrageenan content (% by mass)) is 1.2 to 10
  • the content ratio of starches to gums in the capsule shell (starch content (mass%) / gum content (mass%)) is 1 to 50, [10] or The capsule of [11].
  • the content ratio of starch to iota carrageenan in the capsule shell (starch content (mass%) / iota carrageenan content (mass%)) is 1.2 to 10,
  • the content ratio of starches to gums in the capsule shell (starch content (mass%) / gum content (mass%)) is 1 to 50,
  • the content ratio of iota carrageenan to gums in the capsule shell (content of iota carrageenan (% by mass) / content of gums (% by mass)) is 0.5 to 15 [13] to [16], and the capsule of any one of [13-1].
  • a capsule shell composition and the like with excellent handleability are provided.
  • the capsule shell composition of one aspect of the present invention comprises starches, iota carrageenan, and gums.
  • the iota-carrageenan content is 2% by mass or more with respect to 100% by mass of the capsule shell composition.
  • the content of the gums is 0.3 to 14% by mass with respect to 100% by mass of the capsule shell composition.
  • the capsule shell composition has excellent handleability. Specifically, the capsule shell composition has a suitable viscosity. As a result, for example, the obtained capsules are excellent in formability of a film (wet film) that can be formed during production of the capsules, so that filling suitability is high (for example, high-speed filling is possible) and heat-sealability is excellent. At least one of the effects of high blocking resistance, good appearance, and the like can be obtained.
  • the capsule shell composition may have jelly strength and flexibility suitable for a film (wet coating) formed during production of the capsule. Therefore, at least one of the effects of high strength of the film formed during production of the capsule and high hardness of the resulting capsule can be achieved. Furthermore, in one embodiment, since the capsule shell composition contains starches, high disintegrability can be obtained.
  • the capsule shell composition of the present invention does not contain gelatin. As a result, even those who cannot take gelatin due to religious reasons, vegetarianism, allergies, etc., can take the capsules. Also, safety issues such as mad cow disease are less likely to occur.
  • the capsule shell composition of the present invention does not contain a phosphate buffer.
  • Patent Document 1 it was necessary to adjust the pH with a phosphate buffer in order to prevent destruction (decomposition) of carrageenan, but the capsule shell composition of the present invention does not require such pH adjustment. can be. As a result, the amount of chemical substances such as phosphate buffers can be reduced, so that even health-conscious people can take the capsules.
  • Starch has a film-forming property and functions as a base agent for capsule shells. Since the capsule shell composition uses starches as a base agent, the obtained capsules can have excellent disintegration properties.
  • the starches are not particularly limited, but include natural starch and processed starch.
  • the natural starch is not particularly limited, but includes potato starch, tapioca starch, glutinous corn starch, glutinous rice starch, sago starch, sweet potato starch, mung bean starch, wheat starch and the like.
  • the modified starch is obtained by physically, chemically and enzymatically processing natural starch.
  • Said processing includes, for example, esterification, etherification, oxidation, cross-linking, hydrolysis, and combinations thereof.
  • modified starch examples include esterified starch such as acetylated starch, phosphated starch and octenyl succinic acid starch; etherified starch such as hydroxypropylated starch and sodium starch glycolate; oxidized starch; Esterified crosslinked starch such as phosphate monoesterified phosphate crosslinked starch and starch phosphate sodium; etherified crosslinked starch such as hydroxypropylated starch for phosphorylation; esterified oxidized starch such as acetylated oxidized starch; glucose, starch syrup , maltodextrin, dextrin, and starch hydrolyzate such as roasted dextrin.
  • esterified starch such as acetylated starch, phosphated starch and octenyl succinic acid starch
  • etherified starch such as hydroxypropylated starch and sodium starch glycolate
  • oxidized starch Esterified crosslinked starch
  • the dextrose equivalent (DE) of the starch hydrolyzate is preferably 20 or less, more preferably 15 or less, even more preferably 10 or less, and particularly preferably 5 or less. , more than 0 and less than or equal to 5.
  • DE dextrose equivalent
  • the starch hydrolyzate has a dextrose equivalent of 20 or less, deterioration over time is less likely to occur, which is preferable.
  • the physical properties (filling suitability, heat-sealing property, jelly strength, flexibility, etc.) of a film (wet film) formed during the production of capsules and the physical properties of capsules (hardness, blocking resistance, appearance) are high.
  • D.E. glucose equivalent
  • the amount of reducing sugars in the starch hydrolyzate is measured by the Reine Einone method, the Willstetter-Schudel method, the Bertrand method, or the HPLC method (for example, "Starch Sugar Related Industrial Analysis Method” (Starch Sugar Technical Committee Ed., published by Shokuhin Kagaku Shimbunsha (published on November 1, 1991))).
  • pure glucose D.I. E. is 100, the D.O.D. of undegraded starch (native starch). E. becomes 0.
  • the starch preferably contains at least one selected from the group consisting of natural starch and modified starch, and at least one selected from the group consisting of natural starch, etherified starch, and starch hydrolyzate. More preferably, it contains at least one selected from the group consisting of native starch and etherified starch, and at least one selected from the group consisting of native starch and hydroxypropylated starch. Especially preferred.
  • the above-mentioned starches may be used alone or in combination of two or more.
  • the viscosity of the starch is preferably 200 mPa s or less, more preferably 100 mPa s or less, even more preferably 50 mPa s or less, and particularly preferably 1 to 50 mPa s. Most preferably, it is 20 to 50 mPa ⁇ s. It is preferable that the viscosity of the starch is 200 mPa ⁇ s or less, since the viscosity of the capsule shell composition can be reduced.
  • the "viscosity of starches" means the average value measured by the method described in the Examples.
  • the starch content is preferably 3% by mass or more, more preferably 8% by mass or more, and even more preferably 10% by mass or more, relative to the total mass of the capsule shell composition. , is particularly preferably 15% by mass or more, and most preferably 19% by mass or more.
  • the starch content is preferably 40% by mass or less, more preferably 30% by mass or less, and 22% by mass or less, relative to the total mass of the capsule shell composition. More preferably, yes.
  • the starch content is preferably 3 to 40% by mass, preferably 10 to 30% by mass, and 10 to 25% by mass, based on the total mass of the capsule shell composition. More preferably, 15 to 25% by mass is even more preferable.
  • a starch content of 3% by mass or more is preferable because the capsule shell can be suitably formed.
  • the starch content is 40% by mass or less, it is preferable because the physical properties can be easily adjusted by adding other components (for example, iota carrageenan) to the capsule shell composition.
  • Iota carrageenan Iota ( ⁇ ) carrageenan can form soft, elastic, highly transparent gels with low syneresis. Therefore, iota-carrageenan has the function of improving at least one of jelly strength and flexibility of a film (wet film) formed during production of capsules, hardness and appearance of capsules, and the like.
  • Iota carrageenan has a main chain with a linear structure represented by the following structural formula.
  • iota carrageenan has a linear main chain composed of glasstose having one sulfate group and 3,6-anhydrogalactose having one sulfate group.
  • iota carrageenan may have galactose having two sulfate ester groups, 3,6-anhydrogalactose having no sulfate ester groups, or branched chains in a part of the main chain. may be
  • the viscosity of iota carrageenan is preferably 5000 mPa s or less, more preferably 4000 mPa s or less, still more preferably 500 to 4000 mPa s, particularly preferably 1000 to 3500 mPa s. .
  • Iota-carrageenan having a viscosity of 5000 mPa ⁇ s or less is preferable because the viscosity of the capsule shell composition can be reduced.
  • the "viscosity of iota carrageenan" means the average value measured by the method described in Examples.
  • the content of iota carrageenan is 2% by mass or more, preferably 3% by mass or more, more preferably 4% by mass or more, and 6% by mass, relative to the total mass of the capsule shell composition. It is particularly preferable that it is above.
  • the content of iota carrageenan is preferably 20% by mass or less, more preferably 15% by mass or less, and preferably 10% by mass or less, relative to the total mass of the capsule shell composition. More preferred.
  • the content of iota carrageenan is preferably 2 to 20% by mass, more preferably 3 to 20% by mass, more preferably 4 to 20% by mass, based on the total mass of the capsule shell composition.
  • % by mass is more preferred, 4 to 15% by mass is particularly preferred, 4 to 10% by mass is more preferred, and 6 to 10% by mass is most preferred.
  • content of iota carrageenan is 2% by mass or more, at least one of the jelly strength and flexibility of the film (wet film) formed during production of the capsule, and the hardness and appearance of the capsule can be improved. preferable.
  • content of iota carrageenan is 20% by mass or less, the viscosity of the capsule shell composition can be lowered, which is preferable.
  • iota carrageenan can be obtained by extracting Eucheuma Spinosum, etc.
  • Eucheuma Spinosum is washed with water, pulverized, and boiled to extract iota carrageenan, filtered, isolated, purified, dehydrated, dried, pulverized, and if necessary, sugar or the like is used to obtain iota carrageenan. be able to.
  • isolation, purification and dehydration of iota carrageenan are preferably carried out by a gel press method.
  • the gel press method is a method in which the iota carrageenan extract is cooled to gel the iota carrageenan, and then pressurized and dehydrated.
  • a metal salt such as potassium chloride may be added before cooling and gelling.
  • the gel press method does not allow amino acids, proteins, and relatively low-molecular-weight carbohydrates to be extracted during purification. It is difficult for impurities such as Therefore, the gel press method is less likely to cause the Maillard reaction and accompanying pH reduction, and thus less likely to cause the decomposition of iota carrageenan, so that high-quality iota carrageenan can be obtained.
  • Gums have a function of reducing the viscosity of the capsule shell composition, a function of improving the flexibility of the film (wet film) formed during the manufacture of the capsule, and the like. Gums may exhibit a synergistic effect with the iota carrageenan. For example, gums and iota carrageenan form a double helix structure.
  • the double helix structure is a rigid skeleton having crystalline and amorphous regions, and can stably exist in the wet film and the capsule shell of the capsule.
  • iota carrageenan enhances the jelly strength and flexibility of the wet film, the hardness and appearance of the capsule, suppresses the increase in viscosity of the capsule shell composition due to the addition of iota carrageenan, and prevents the decomposition of iota carrageenan. At least one effect of performing, etc. can be further exhibited.
  • the gums are preferably one or more selected from the group consisting of gum arabic, guar gum, locust bean gum, gellan gum, xanthan gum, and tamarind gum, and are selected from the group consisting of gum arabic, guar gum, and gellan gum. It is more preferably one or more, and one or more selected from the group consisting of gum arabic and gellan gum from the viewpoint of improving the jelly strength and flexibility of the resulting wet film and the hardness of the resulting capsule. More preferably, it contains gum arabic. In addition, gums may be used individually or may be used in combination of 2 or more types.
  • Gum arabic is mainly composed of polysaccharides and includes arabinogalactan, arabinogalactan protein, glycoprotein, and the like.
  • Guar gum is a polysaccharide having two molecules of mannose linked in a linear chain and one molecule of galactose as a side chain.
  • the guar gum may be a guar gum derivative, and examples of the guar gum derivative include hydroxypropyl guar gum, cationized guar gum, and guar gum enzymatic decomposition products.
  • Locust bean gum is a polysaccharide having 4 molecules of mannose linked in a straight chain and a side chain of 1 molecule of galactose.
  • Gellan gum includes high acyl gellan gum and low acyl gellan gum.
  • the high-acyl gellan gum is also called native gellan gum, and has a structure in which acyl groups are bound to constituent sugars (mainly glucose).
  • the low acyl gellan gum is also called deacylated gellan gum, and is obtained by deacylating high acyl gellan gum.
  • gellan gum is preferably low acyl gellan gum from the viewpoint of its low gelation temperature and suitability for capsule production.
  • Xanthan gum has a repeating unit structure of two molecules of glucose, two molecules of mannose, and glucuronic acid.
  • Tamarind gum is a polysaccharide with a structure called xyloglucan, which contains glucose in the main chain and xylose and galactose in the side chains.
  • the content of gums is 0.3 to 14% by mass, preferably 0.3 to 7.5% by mass, and 1 to 7.5% by mass, relative to the total mass of the capsule shell composition. %, more preferably 1 to 4% by mass. It is preferable that the content of the gums is within the above range, since the viscosity of the capsule shell composition can be lowered.
  • at least one of the physical properties of the film (wet film) formed during capsule production (filling suitability, heat-sealing property, jelly strength, flexibility, etc.) and the physical properties of the capsule (hardness, blocking resistance, appearance) It is preferable because it can be improved.
  • the content ratio of starches to iota carrageenan is preferably 1 to 20, preferably 1.2 to 10 is more preferred, 1.2 to 5 is even more preferred, and 2 to 5 is particularly preferred.
  • the content ratio of starches to gums is preferably 1 to 75, preferably 1 to 50. It is more preferably 1, more preferably 2 to 50, particularly preferably 2 to 40, and most preferably 5 to 30.
  • the content ratio of iota carrageenan to gums is preferably 0.1 to 30. It is more preferably from 5 to 15, even more preferably from 1 to 25, particularly preferably from 2 to 25, and most preferably from 2 to 12.
  • the total content of starches and iota carrageenan is preferably 5 to 40% by mass, more preferably 10 to 40% by mass, based on the total mass of the capsule shell composition. , more preferably 22 to 40% by mass, particularly preferably 26 to 40% by mass.
  • the total content of starches and gums is preferably 3.5 to 40% by mass, preferably 5 to 35% by mass, based on the total mass of the capsule shell composition. It is more preferably 15 to 30% by mass, particularly preferably 15 to 25% by mass, and most preferably 21 to 25% by mass.
  • the total content of iota carrageenan and gums is preferably 2.5 to 30% by weight, preferably 2.5 to 20% by weight, based on the total weight of the capsule shell composition. is more preferable, 2.5 to 15% by mass is more preferable, and 2.5 to 10% by mass is particularly preferable.
  • the capsule shell composition preferably further comprises alginate.
  • the alginate can improve the jelly strength of the film (wet film) formed during capsule production and the hardness of the physical properties of the capsule while suppressing the increase in the viscosity of the capsule shell composition.
  • a synergistic effect between alginic acid ester and gums is considered.
  • the action of alginate on proteins, which are constituents of gums will further improve the effect of suppressing increases in the viscosity of capsule shell compositions due to the addition of iota-carrageenan contained in gums.
  • Alginic acid ester is a linear polysaccharide polymerized from two types of uronic acid ( ⁇ -D-mannuronic acid (M) and ⁇ -L-guluronic acid (G)). has an ester-bonded structure.
  • Alginate has a surface active effect because it has a hydrophilic alginic acid portion and a lipophilic propylene glycol portion.
  • the alginate content is 0.001% by mass or more, preferably 0.01% by mass or more, and preferably 0.03% by mass or more, relative to the total mass of the capsule shell composition. More preferably, it is particularly preferably 0.3% by mass or more.
  • the alginate content is preferably 10% by mass or less, more preferably 5% by mass or less, and 0.75% by mass or less, relative to the total mass of the capsule shell composition. is particularly preferred.
  • the alginate content is preferably 0.001 to 10% by mass, more preferably 0.001 to 5% by mass, relative to the total mass of the capsule shell composition. , more preferably 0.01 to 5% by mass, and particularly preferably 0.03 to 0.75% by mass.
  • the jelly strength of the film (wet film) formed during the production of the capsules and the hardness of the physical properties of the capsules are improved while suppressing an increase in the viscosity of the capsule shell composition. can be improved.
  • the content ratio of gums to alginate is preferably 0.01 to 100, and 0.1 to 50. is more preferred, 0.5 to 20 is even more preferred, and 3 to 20 is particularly preferred.
  • the capsule shell composition preferably further comprises a plasticizer.
  • a plasticizer has the function of imparting flexibility to the film (wet film) formed during the production of capsules.
  • Plasticizers include, but are not limited to, polyhydric alcohols such as glycerin, sorbitol, maltitol, ethylene glycol, propylene glycol; hydroxymethylcellulose (HPMC), hydroxypropylcellulose (HPC), methylcellulose (MC), carboxymethylcellulose (CMC); ) and other cellulose derivatives.
  • the plasticizer preferably contains a polyhydric alcohol, and more preferably contains glycerin. These plasticizers may be used alone or in combination of two or more.
  • the content of the plasticizer is preferably 1 to 50% by mass, more preferably 5 to 30% by mass, and 5 to 25% by mass, relative to the total mass of the capsule shell composition. is more preferred. It is preferable that the content of the plasticizer is within the above range, since the flexibility of the wet film becomes suitable.
  • the capsule shell composition may further comprise gelatin.
  • gelatin By including gelatin in the capsule shell composition, it is possible to improve the viscosity and flowability of the capsule shell composition, the strength of the formed capsule shell, the heat-sealing property, the resistance to cracking, and the like.
  • gelatin examples include, but are not limited to, pig gelatin, bovine gelatin, fish gelatin, gelatin derivatives, and the like.
  • gelatin derivatives include succinated gelatin, gelatin hydrolysates, and crosslinked gelatin. These gelatins may be used alone or in combination of two or more. For example, by using fish gelatin or a derivative thereof, it may be possible to ingest animal collagen even in cases where it is difficult to ingest animal collagen from the viewpoint of religion, vegetarianism, allergies, or the like.
  • the gelatin content is preferably 40% by mass or less, more preferably 30% by mass or less, and even more preferably 1 to 20% by mass, relative to the total mass of the capsule shell composition. .
  • the capsule shell composition preferably contains a solvent.
  • a solvent in the capsule shell composition, the viscosity of the capsule shell composition can be adjusted.
  • solvents include water and organic solvents.
  • the organic solvent is not particularly limited, but includes ethanol, isopropyl alcohol, acetone, ethyl butyrate, and the like.
  • the solvent preferably contains water.
  • the above-mentioned solvent may be used independently or may be used in combination of 2 or more types.
  • the content of the solvent is preferably 20 to 90% by mass, more preferably 30 to 80% by mass, and 40 to 70% by mass, based on the total mass of the capsule shell composition. More preferably, it is particularly preferably 50 to 60% by mass.
  • the capsule shell composition may contain additives.
  • Such additives include other thickeners, pH adjusters, sequestering agents, film coloring agents, corrigents, sweeteners, preservatives, flavoring agents, and the like.
  • Olether thickeners means thickeners other than iota carrageenan, gums, gelatin, and alginate.
  • the other thickening agents include, but are not limited to, kappa ( ⁇ ) carrageenan, lambda ( ⁇ ) carrageenan, pullulan, agar, alginic acid, sodium alginate, and the like. These other thickening agents may be used alone or in combination of two or more.
  • Kappa-carrageenan has a linear main chain composed of galactose having one sulfate ester group and 3,6-anhydrogalactose having no sulfate ester group.
  • kappa carrageenan may have galactose having two sulfate ester groups, 3,6-anhydrogalactose having sulfate ester groups in part of the main chain, or may have a branched chain. good too.
  • lambda carrageenan has a main chain with a linear structure composed of galactose with two sulfate ester groups and galactose with one sulfate ester group.
  • Lambda carrageenan may have 3,6-anhydrogalactose having a sulfate ester group, 3,6-anhydrogalactose having no sulfate ester group, or branched It may have chains.
  • the pH adjuster is not particularly limited, but includes acids such as hydrochloric acid, sulfuric acid, and nitric acid; bases such as sodium hydroxide and potassium hydroxide; buffers such as phosphate buffers and Tris buffers. These pH adjusters may be used alone or in combination of two or more.
  • the capsule shell composition preferably does not contain a buffering agent, and more preferably does not contain a phosphate buffering agent.
  • sequestering agents include citric acid, tartaric acid, lactic acid, phosphoric acid, acetic acid, gluconic acid, ethylenediaminetetraacetic acid, metaphosphoric acid, salts thereof; glycine, and the like.
  • additives may be used alone or in combination of two or more.
  • the method for producing the capsule shell composition is not particularly limited, and it can be produced by a known method.
  • starch, iota carrageenan, gums, and if necessary, alginate, plasticizer, gelatin, and additives are added to a solvent, and the resulting suspension is heated and dissolved to form a capsule shell composition. can manufacture things.
  • capsules are provided.
  • the capsule includes contents and a capsule shell.
  • a capsule shell is formed using the capsule shell composition described above.
  • a capsule containing contents and a capsule shell containing starches, iota carrageenan, and gums.
  • the capsule has a hardness of 15 kg or more.
  • the capsule shell may further contain at least one of alginate, plasticizer, gelatin, solvent and additive.
  • Contents are not particularly limited, and include active ingredients and additives.
  • Examples of the active ingredient include, but are not limited to, hypnotics, psychotropic drugs, antiepileptic drugs, antiparkinsonian drugs, analgesics, therapeutic drugs for Alzheimer's disease, antiallergic drugs, cardiotonic drugs, antiarrhythmic drugs, and antianginal drugs.
  • Anticancer drugs Antifungal drugs Immunosuppressive drugs Crude drugs such as senega, clove, angelica gentian, gentian, ryutan, assembly, rhubarb, digitalis, valerian, bellflower, aloe, hange, turmeric, ginger; Herbal medicines such as shakuyakusan and maoto; vitamins, minerals, collagen, coenzyme Q10, DHA, EPA, lutein, blueberry, placenta, soybean isoflavone, lactic acid bacteria, bifidobacteria, and other health-promoting ingredients; caryophyllene, menthol, limonene, Aroma components such as sesquiterpene and vanill
  • the additives include, but are not particularly limited to, excipients, coloring agents, masking agents, sweeteners, antioxidants, preservatives, lubricants, flavoring agents, and the like. These additives may be used alone or in combination of two or more.
  • the total mass of the contents is preferably 40-90% by mass, more preferably 50-80% by mass, relative to the total mass of the capsule.
  • a capsule shell is formed using a capsule shell composition.
  • the capsule shell comprises starches, iota carrageenan, and gums.
  • the capsule shell may further contain at least one of alginate, plasticizer, gelatin, solvent, and additives.
  • the capsule shell does not contain gelatin. Moreover, it is preferable that the capsule shell does not contain a phosphate buffer.
  • the film thickness of the capsule shell is preferably 200 ⁇ m or more, more preferably 250 to 800 ⁇ m, even more preferably 250 to 500 ⁇ m.
  • the film thickness of the capsule film can be measured using a digital microscope (for example, trade name VHX-900 manufactured by Keyence Corporation, using a 10 ⁇ m calibration scale). can.
  • the total mass of the capsule shell is preferably 10-60% by mass, more preferably 20-50% by mass, relative to the total mass of the capsule.
  • the content ratio of starch to iota carrageenan in the capsule shell is preferably 1 to 20, It is more preferably from 1.2 to 10, even more preferably from 1.2 to 5, and particularly preferably from 2 to 5.
  • the content ratio of starches to gums in the capsule shell is preferably 1 to 75, It is more preferably from 1 to 50, even more preferably from 2 to 50, particularly preferably from 2 to 30, and most preferably from 5 to 30.
  • the content ratio of iota-carrageenan to gums in the capsule shell is 0.1 to 30. It is preferably from 0.5 to 15, even more preferably from 1 to 25, particularly preferably from 2 to 25, and most preferably from 2 to 12.
  • the starch content (% by mass), the iota carrageenan content (% by mass), and the gum content (% by mass) in the capsule shell are the contents of each component with respect to 100% by mass of the capsule shell. means.
  • each content ratio can correspond to each content ratio in the capsule shell composition.
  • the shape of the capsule is not particularly limited, but may be spherical, ellipsoidal, triangular, rhomboidal, rectangular parallelepiped, rectangular parallelepiped, or the like.
  • the capsule is preferably a soft capsule.
  • a soft capsule By being a soft capsule, it is possible to obtain effects such as the ability to formulate a liquid active ingredient with a large amount of oil, a high degree of freedom in the shape of the capsule, and the ability to print the product name on the capsule surface.
  • the hardness of the capsule is preferably 10 kg or more, more preferably 15 kg or more, still more preferably 20 kg or more, particularly preferably 22 kg or more, and preferably 24 kg or more and 25 kg or more. Most preferred.
  • the upper limit of hardness of the capsule is, for example, preferably 40 kg or less, more preferably 35 kg or less, and even more preferably 30 kg or less. Due to the high hardness of the capsule, deformation of the capsule can be suppressed during storage and distribution.
  • a method for producing capsules is provided.
  • the method for producing capsules is not particularly limited, but includes a filling step of filling the capsule shell composition described above with a content liquid containing an active ingredient, and a drying step of drying the resulting filling.
  • the filling step is a step of filling the capsule shell composition described above with a content liquid containing an active ingredient.
  • the content liquid contains active ingredients.
  • additives may be further included. Said active ingredients and additives are as described above.
  • capsule shell composition is as described above.
  • the filling method is not particularly limited, but it is preferably a random punching method.
  • the stamping process is usually performed using rotary manufacturing equipment. More specifically, the punching method involves sandwiching two skin sheets obtained from a capsule shell composition between a pair of cylindrical molds so as to overlap each other, and injecting the liquid content between the two skin sheets. In this method, pressure cutting and crimping are performed simultaneously using a mold.
  • the capsule shell composition according to the present invention has a low viscosity and is excellent in handleability.
  • excellent filling suitability for example, high-speed filling is possible
  • excellent moldability of a film (wet film) that can be formed during the production of capsules
  • excellent heat sealability There are two effects.
  • the capsule shell composition may have a jelly strength and flexibility suitable for the film formed during production of the capsule. Therefore, it is possible to obtain effects such as high strength of the film formed during production of the capsule.
  • a drying process is a process of drying the obtained filling.
  • the resulting filling has a structure in which the content liquid is filled in the wet film.
  • the capsule shell can be obtained by removing mainly the moisture contained in the wet coating.
  • the temperature and relative humidity during drying are not particularly limited, it is performed in an environment with a temperature of 25-45°C and a relative humidity of 30% RH or less.
  • the drying process is preferably carried out until the water content of the capsule shell falls below 15%.
  • Example 1 Starch (viscosity: 46 ⁇ 5 mPa s), iota carrageenan (viscosity: 2,600 ⁇ 800 mPa s), gum arabic gum (viscosity: 260 ⁇ 80 mPa s), and glycerin as a plasticizer , was mixed with water at the compounding ratio shown in Table 1, and the resulting suspension was stirred and dissolved under heating at 90°C or higher for 3 hours to prepare a capsule shell composition.
  • the viscosity of starches, the viscosity of iota carrageenan, and the viscosity of gums were measured by the following methods.
  • Viscosity of gums 25 g of gums and 75 g of purified water were placed in a beaker and mixed well with a stirrer. The prepared mixed solution is No. After transferring to a 12 standard bottle and adjusting the mixture to 25° C., the viscosity was measured. The viscosity was measured with a Brookfield viscometer (Brookfield DV-E, liquid temperature 25° C., rotor No. 2, value after rotating at 60 rpm for 1 minute) using the obtained 25% mixture. . In addition, in this example, the viscosity of gums was measured 3 times, and was described as the average value ⁇ SD (standard deviation).
  • Examples 2 to 15, Comparative Examples 1 to 6 A capsule shell composition was produced in the same manner as in Example 1, except that the compounding ratios shown in Tables 1 and 2 were changed.
  • the raw materials used are as follows.
  • Guar gum was manufactured by Unitech Foods Co., Ltd., and gellan gum was manufactured by Sumitomo Pharma Food & Chemical Co., Ltd., respectively.
  • Viscosity was evaluated for the capsule shell compositions produced in Examples 1-15 and Comparative Examples 1-6. Also, the wet film formed from the capsule shell composition was evaluated for jelly strength, flexibility, and filling suitability. Furthermore, hardness, blocking resistance, appearance, and disintegrability were evaluated for soft capsules produced using the capsule shell composition.
  • Capsule composition (viscosity) The viscosities of the capsule shell compositions produced in Examples 1 to 15 and Comparative Examples 1 to 6 were measured using a Brookfield viscometer (TVB-15 manufactured by Toki Sangyo Co., Ltd., liquid temperature 95° C., rotor No. H7, 12 rpm. value after rotating for 1 minute). In addition, in this example, the viscosity of the capsule shell composition was measured three times, and was described as the mean ⁇ SD (standard deviation).
  • Brookfield viscometer Brookfield viscometer
  • Soft capsules production of soft capsules
  • the capsule shell compositions produced in Examples 1 to 15 and Comparative Examples 1 to 6 were filled with medium-chain fatty acid triglycerides using a rotary die capsule filling machine to obtain football-shaped wet capsules. .
  • the resulting wet capsules were dried in a dryer set at 40 ⁇ 2° C. and a humidity of less than 20% to produce soft capsules.
  • the moisture content of the capsule shell of the soft capsule after drying was set to 10 ⁇ 1% by weight.
  • the water content was calculated by the following method.
  • the hardness of the soft capsule prepared above was evaluated using a Monsanto type tablet hardness tester (B type 30 kg) 208-0219-B manufactured by Ohiwa Pharmaceutical Machinery Co., Ltd. Specifically, pressure was applied to the soft capsule using the tablet hardness tester, and the load (hardness) applied when the soft capsule was broken was measured. In this example, the hardness was measured three times, and the average value ⁇ SD (standard deviation) was described.
  • the inner stopper and metal cap of the bottle were removed, and the following conditions A to E were operated in order starting from A, and the evaluation result was the condition when all 20 soft capsules fell out of the bottle.
  • the blocking resistance is high, that is, the surface of the soft capsules is less sticky and the soft capsules are less likely to adhere to each other.
  • the capsule shell compositions of Examples 1-15 had low viscosities. Also, although the viscosity of the capsule shell composition was low, the jelly strength and flexibility of the wet coating were high. For this reason, it is considered that filling suitability is good and, for example, high-speed filling becomes possible. Also, the hardness of the soft capsule was high. In addition, the soft capsules were found to have high blocking resistance, good appearance, and excellent disintegration properties.

Abstract

Provided is a capsule shell composition and the like having excellent handleability. The capsule shell composition comprises a starch, iota carrageenan, and a gum, wherein the content of the carrageenan is 2 mass% or higher with respect to the capsule shell composition, which is taken as 100 mass%, and the content of the gum is 0.3-14 mass% with respect to the capsule shell composition, which is taken as 100 mass%.

Description

カプセル剤皮組成物およびこれを用いたカプセル剤Capsule shell composition and capsules using the same
 本発明は、カプセル剤皮組成物およびこれを用いたカプセル剤に関する。 The present invention relates to a capsule shell composition and capsules using the same.
 従来、カプセル皮膜の製造に使用されるカプセル剤皮組成物には、ゼラチンが好適に使用される。ゼラチンは、カプセル剤皮組成物の粘度および流動性、形成されるカプセル皮膜の強度、ヒートシール性、割れ耐性等において好適な物性を示す。 Conventionally, gelatin is suitably used for the capsule shell composition used in the production of capsule shells. Gelatin exhibits suitable physical properties such as the viscosity and fluidity of the capsule shell composition, the strength of the formed capsule shell, heat-sealing properties, and resistance to cracking.
 しかしながら、ゼラチンは、その多くが動物性コラーゲンに由来するため、近年、宗教、菜食主義、アレルギー、狂牛病等の観点から、ゼラチンに変わる原材料を主成分として用いるカプセル剤皮組成物が求められている。 However, gelatin is mostly derived from animal collagen, and in recent years, from the viewpoint of religion, vegetarianism, allergies, mad cow disease, etc., there has been a demand for a capsule shell composition that uses a raw material that replaces gelatin as a main component. ing.
 このようなカプセル剤皮組成物として、例えば、特許文献1には、イオタカラギーナンと改質澱粉との混合物と、水と可塑剤と、緩衝剤とを含有する軟質カプセルに適する乾燥フィルム組成物(カプセル剤皮組成物)に係る発明が記載されている。 As such a capsule shell composition, for example, Patent Document 1 discloses a dry film composition suitable for soft capsules containing a mixture of iota carrageenan and modified starch, water, a plasticizer, and a buffer ( An invention relating to a capsule shell composition) is described.
 特許文献1には、前記カプセル剤皮組成物が、機械的に丈夫であると共に充填(ブロー成形)に際しフィルムを延伸させるのに充分な弾力性を示すフィルムを形成することが記載されている。なお、特許文献1には、緩衝剤(リン酸塩緩衝剤)は、カラギーナンの破壊(分解)を防ぐ目的で添加されることが記載されている。 Patent Document 1 describes that the capsule shell composition forms a film that is mechanically tough and has sufficient elasticity to stretch the film during filling (blow molding). Patent Document 1 describes that a buffer (phosphate buffer) is added for the purpose of preventing destruction (decomposition) of carrageenan.
特表2003-504326号公報Japanese Patent Publication No. 2003-504326
 しかしながら、特許文献1に記載のカプセル剤皮組成物は、粘度が高く、取り扱い性に劣る場合があった。そこで、取り扱い性に優れるカプセル剤皮組成物が求められている。 However, the capsule shell composition described in Patent Document 1 has high viscosity and is sometimes inferior in handleability. Therefore, there is a demand for a capsule shell composition that is easy to handle.
 本発明は、例えば、以下の態様を含む。 The present invention includes, for example, the following aspects.
 [1]澱粉類、イオタカラギーナン、およびガム類を含む、カプセル剤皮組成物であって、
 前記イオタカラギーナンの含有量が、前記カプセル剤皮組成物100質量%に対して、2質量%以上であり、
 前記ガム類の含有量が、前記カプセル剤皮組成物100質量%に対して、0.3~14質量%である、カプセル剤皮組成物。
 [2]ゼラチンを含まない、上記[1]に記載のカプセル剤皮組成物。
 [3]リン酸塩緩衝剤を含まない、上記[1]または[2]に記載のカプセル剤皮組成物。
 [4]前記ガム類が、アラビアガム、グァーガム、ローカストビーンガム、ジェランガム、キサンタンガム、およびタマリンドガムからなる群から選択される1種以上である、上記[1]~[3]のいずれかに記載のカプセル剤皮組成物。
 [5]イオタカラギーナンに対する澱粉類の含有量比(澱粉類の含有量(質量%)/イオタカラギーナンの含有量(質量%))が、1.2~10であり、
 ガム類に対する澱粉類の含有量比(澱粉類の含有量(質量%)/ガム類の含有量(質量%))が、1~50であり、
 ガム類に対するイオタカラギーナンの含有量比(イオタカラギーナンの含有量(質量%)/ガム類の含有量(質量%))が、0.5~15である、上記[1]~[4]のいずれかに記載のカプセル剤皮組成物。
 [6]前記澱粉類の含有量が、カプセル剤皮組成物100質量%に対して、10~30質量%であり、
 前記イオタカラギーナンの含有量が、前記カプセル剤皮組成物100質量%に対して、2~20質量%である、上記[1]~[5]のいずれかに記載のカプセル剤皮組成物。
 [7]アルギン酸エステルをさらに含む、上記[1]~[6]のいずれかに記載のカプセル剤皮組成物。
 [8]可塑剤をさらに含む、上記[1]~[7]のいずれかに記載のカプセル剤皮組成物。
 [9]前記澱粉類が、天然澱粉および加工澱粉からなる群から選択される少なくとも1種を含む、上記[1]~[8]のいずれかに記載のカプセル剤皮組成物。
 [10]内容物と、カプセル皮膜と、を含むカプセル剤であって、
 前記カプセル皮膜が、上記[1]~[9]のいずれかに記載のカプセル剤皮組成物を用いて形成される、カプセル剤。
 [11]軟カプセル剤である、上記[10]に記載のカプセル剤。
 [12]前記カプセル皮膜中のイオタカラギーナンに対する澱粉類の含有量比(澱粉類の含有量(質量%)/イオタカラギーナンの含有量(質量%))が、1.2~10であり、
 前記カプセル皮膜中のガム類に対する澱粉類の含有量比(澱粉類の含有量(質量%)/ガム類の含有量(質量%))が、1~50であり、
 前記カプセル皮膜中のガム類に対するイオタカラギーナンの含有量比(イオタカラギーナンの含有量(質量%)/ガム類の含有量(質量%))が、0.5~15である、上記[10]または[11]に記載のカプセル剤。
 [13]内容物と、
 澱粉類、イオタカラギーナン、およびガム類を含む、カプセル皮膜と、
を含み、
 硬度が15kg以上である、カプセル剤。
 [13-1]内容物と、
 上記[1]~[9]のいずれかに記載のカプセル剤皮組成物を用いて形成されるカプセル皮膜と、
を含み、
 硬度が15kg以上である、カプセル剤。
 [14]前記カプセル皮膜が、ゼラチンを含まない、上記[13]または[13-1]に記載のカプセル剤。
 [15]前記カプセル皮膜が、リン酸塩緩衝剤を含まない、上記[13]、[13-1]、または[14]に記載のカプセル剤。
 [16]軟カプセル剤である、上記[13]~[15]、および[13-1]のいずれかに記載のカプセル剤。
 [17]前記カプセル皮膜中のイオタカラギーナンに対する澱粉類の含有量比(澱粉類の含有量(質量%)/イオタカラギーナンの含有量(質量%))が、1.2~10であり、
 前記カプセル皮膜中のガム類に対する澱粉類の含有量比(澱粉類の含有量(質量%)/ガム類の含有量(質量%))が、1~50であり、
 前記カプセル皮膜中のガム類に対するイオタカラギーナンの含有量比(イオタカラギーナンの含有量(質量%)/ガム類の含有量(質量%))が、0.5~15である、上記[13]~[16]、および[13-1]のいずれかに記載のカプセル剤。
[1] A capsule shell composition comprising starches, iota carrageenan, and gums,
The content of the iota carrageenan is 2% by mass or more with respect to 100% by mass of the capsule shell composition,
A capsule shell composition, wherein the gum content is 0.3 to 14% by mass with respect to 100% by mass of the capsule shell composition.
[2] The capsule shell composition according to [1] above, which does not contain gelatin.
[3] The capsule shell composition according to [1] or [2] above, which does not contain a phosphate buffer.
[4] Any one of [1] to [3] above, wherein the gum is one or more selected from the group consisting of gum arabic, guar gum, locust bean gum, gellan gum, xanthan gum, and tamarind gum. capsule shell composition.
[5] The content ratio of starch to iota carrageenan (starch content (% by mass)/iota carrageenan content (% by mass)) is 1.2 to 10,
The content ratio of starches to gums (starch content (mass%) / gum content (mass%)) is 1 to 50,
Any of the above [1] to [4], wherein the content ratio of iota carrageenan to gums (content of iota carrageenan (% by mass) / content of gums (% by mass)) is 0.5 to 15 2. The capsule shell composition according to 1.
[6] the starch content is 10 to 30% by mass with respect to 100% by mass of the capsule shell composition;
The capsule shell composition according to any one of [1] to [5] above, wherein the iota carrageenan content is 2 to 20% by mass with respect to 100% by mass of the capsule shell composition.
[7] The capsule shell composition according to any one of [1] to [6] above, further comprising alginate.
[8] The capsule shell composition according to any one of [1] to [7] above, further comprising a plasticizer.
[9] The capsule shell composition according to any one of [1] to [8] above, wherein the starch contains at least one selected from the group consisting of natural starch and modified starch.
[10] A capsule containing a content and a capsule shell,
A capsule, wherein the capsule shell is formed using the capsule shell composition according to any one of [1] to [9] above.
[11] The capsule of [10] above, which is a soft capsule.
[12] The content ratio of starch to iota carrageenan in the capsule shell (starch content (% by mass) / iota carrageenan content (% by mass)) is 1.2 to 10,
The content ratio of starches to gums in the capsule shell (starch content (mass%) / gum content (mass%)) is 1 to 50,
[10] or The capsule of [11].
[13] contents;
a capsule shell comprising starches, iota carrageenan, and gums;
including
A capsule having a hardness of 15 kg or more.
[13-1] Contents,
a capsule shell formed using the capsule shell composition according to any one of [1] to [9] above;
including
A capsule having a hardness of 15 kg or more.
[14] The capsule of [13] or [13-1] above, wherein the capsule shell does not contain gelatin.
[15] The capsule of [13], [13-1], or [14] above, wherein the capsule shell does not contain a phosphate buffer.
[16] The capsule of any one of [13] to [15] and [13-1] above, which is a soft capsule.
[17] The content ratio of starch to iota carrageenan in the capsule shell (starch content (mass%) / iota carrageenan content (mass%)) is 1.2 to 10,
The content ratio of starches to gums in the capsule shell (starch content (mass%) / gum content (mass%)) is 1 to 50,
The content ratio of iota carrageenan to gums in the capsule shell (content of iota carrageenan (% by mass) / content of gums (% by mass)) is 0.5 to 15 [13] to [16], and the capsule of any one of [13-1].
 本発明によれば、取り扱い性に優れるカプセル剤皮組成物等が提供される。 According to the present invention, a capsule shell composition and the like with excellent handleability are provided.
 以下、本発明を実施するための形態について詳細に説明する。 Hereinafter, the embodiments for carrying out the present invention will be described in detail.
 1 カプセル剤皮組成物
 本発明の一態様のカプセル剤皮組成物は、澱粉類、イオタカラギーナン、およびガム類を含む。この際、前記イオタカラギーナンの含有量が、前記カプセル剤皮組成物100質量%に対して、2質量%以上である。また、前記ガム類の含有量が、前記カプセル剤皮組成物100質量%に対して、0.3~14質量%である。
1 Capsule Shell Composition The capsule shell composition of one aspect of the present invention comprises starches, iota carrageenan, and gums. At this time, the iota-carrageenan content is 2% by mass or more with respect to 100% by mass of the capsule shell composition. Also, the content of the gums is 0.3 to 14% by mass with respect to 100% by mass of the capsule shell composition.
 前記カプセル剤皮組成物は、取り扱い性に優れる。具体的には、カプセル剤皮組成物は、好適な粘度を有する。これにより、例えば、カプセル剤の製造時において成形されうるフィルム(湿潤皮膜)の成形性に優れるため充填適正が高い(例えば、高速充填が可能となる)、ヒートシール性に優れる、得られるカプセル剤のブロッキング耐性が高い、外観が良好となる等のうち少なくとも1つの効果を奏しうる。
 また、一実施形態において、前記カプセル剤皮組成物は、カプセル剤の製造時において形成されるフィルム(湿潤皮膜)が好適なゼリー強度および柔軟性を有しうる。このため、カプセル剤の製造時において形成されるフィルムの強度が高い、得られるカプセル剤の硬度が高い等のうち少なくとも1つの効果を奏しうる。
 さらに、一実施形態において、前記カプセル剤皮組成物は、澱粉類を含むため、高い崩壊性が得られうる。
The capsule shell composition has excellent handleability. Specifically, the capsule shell composition has a suitable viscosity. As a result, for example, the obtained capsules are excellent in formability of a film (wet film) that can be formed during production of the capsules, so that filling suitability is high (for example, high-speed filling is possible) and heat-sealability is excellent. At least one of the effects of high blocking resistance, good appearance, and the like can be obtained.
In one embodiment, the capsule shell composition may have jelly strength and flexibility suitable for a film (wet coating) formed during production of the capsule. Therefore, at least one of the effects of high strength of the film formed during production of the capsule and high hardness of the resulting capsule can be achieved.
Furthermore, in one embodiment, since the capsule shell composition contains starches, high disintegrability can be obtained.
 一実施形態において、本発明のカプセル剤皮組成物は、ゼラチンを含まない。これにより、宗教、菜食主義、アレルギー等の観点からゼラチン摂取をできない者であってもカプセル剤を好適に服用しうる。また、狂牛病といった安全性の問題も生じにくい。 In one embodiment, the capsule shell composition of the present invention does not contain gelatin. As a result, even those who cannot take gelatin due to religious reasons, vegetarianism, allergies, etc., can take the capsules. Also, safety issues such as mad cow disease are less likely to occur.
 一実施形態において、本発明のカプセル剤皮組成物は、リン酸塩緩衝剤を含まない。特許文献1では、カラギーナンの破壊(分解)を防ぐために、リン酸塩緩衝剤によりpHを調整することが必要であったが、本発明のカプセル剤皮組成物ではそのようなpHの調整は不要となりうる。その結果、リン酸塩緩衝剤のような化学物質の添加量を低減することができるため、健康志向を有する者であってもカプセル剤を好適に服用しうる。 In one embodiment, the capsule shell composition of the present invention does not contain a phosphate buffer. In Patent Document 1, it was necessary to adjust the pH with a phosphate buffer in order to prevent destruction (decomposition) of carrageenan, but the capsule shell composition of the present invention does not require such pH adjustment. can be. As a result, the amount of chemical substances such as phosphate buffers can be reduced, so that even health-conscious people can take the capsules.
 以下、カプセル剤皮組成物の各成分について詳細に説明する。 Each component of the capsule shell composition will be described in detail below.
 [澱粉類]
 澱粉類は、皮膜形成性を有し、カプセル皮膜のベース剤としての機能等を有する。なお、カプセル剤皮組成物は、澱粉類をベース剤として用いるため、得られるカプセル剤は優れた崩壊性を有しうる。
[Starches]
Starch has a film-forming property and functions as a base agent for capsule shells. Since the capsule shell composition uses starches as a base agent, the obtained capsules can have excellent disintegration properties.
 澱粉類としては、特に制限されないが、天然澱粉および加工澱粉が挙げられる。 The starches are not particularly limited, but include natural starch and processed starch.
 前記天然澱粉としては、特に制限されないが、馬鈴薯澱粉、タピオカ澱粉、もちとうもろこし澱粉、もち米澱粉、サゴ澱粉、甘藷澱粉、緑豆澱粉、小麦澱粉等が挙げられる。 The natural starch is not particularly limited, but includes potato starch, tapioca starch, glutinous corn starch, glutinous rice starch, sago starch, sweet potato starch, mung bean starch, wheat starch and the like.
 前記加工澱粉は、天然澱粉を物理的、化学的、酵素的に加工処理したものである。前記加工としては、例えば、エステル化、エーテル化、酸化、架橋、加水分解およびこれらの組み合わせが挙げられる。 The modified starch is obtained by physically, chemically and enzymatically processing natural starch. Said processing includes, for example, esterification, etherification, oxidation, cross-linking, hydrolysis, and combinations thereof.
 加工澱粉の具体例としては、アセチル化澱粉、リン酸化澱粉、オクテニルコハク酸澱粉等のエステル化澱粉;ヒドロキシプロピル化澱粉、澱粉グリコール酸ナトリウム等のエーテル化澱粉;酸化澱粉;アセチル化リン酸架橋澱粉、リン酸モノエステル化リン酸架橋澱粉、澱粉リン酸エステルナトリウム等のエステル化架橋澱粉;ヒドロキシプロピル化リン酸化用澱粉等のエーテル化架橋澱粉;アセチル化酸化澱粉等のエステル化酸化澱粉;ブドウ糖、水あめ、マルトデキストリン、デキストリン、焙焼デキストリン等の澱粉分解物等が挙げられる。 Specific examples of modified starch include esterified starch such as acetylated starch, phosphated starch and octenyl succinic acid starch; etherified starch such as hydroxypropylated starch and sodium starch glycolate; oxidized starch; Esterified crosslinked starch such as phosphate monoesterified phosphate crosslinked starch and starch phosphate sodium; etherified crosslinked starch such as hydroxypropylated starch for phosphorylation; esterified oxidized starch such as acetylated oxidized starch; glucose, starch syrup , maltodextrin, dextrin, and starch hydrolyzate such as roasted dextrin.
 なお、澱粉分解物のデキストロース当量(D.E.)は、20以下であることが好ましく、15以下であることがより好ましく、10以下であることがさらに好ましく、5以下であることが特に好ましく、0超5以下であることが最も好ましい。澱粉分解物のデキストロース当量が20以下であると、経時的な劣化が起こりにくくなることから好ましい。これにより、例えば、カプセル剤の製造時に形成されるフィルム(湿潤皮膜)の物性(充填適正、ヒートシール性、ゼリー強度、柔軟性等)およびカプセル剤の物性(硬度、ブロッキング耐性、外観)が高くなる、カプセル剤の黄色~褐色への変色を防止できる等の効果が得られうる。なお、本明細書において「デキストロース当量(D.E.)」とは、澱粉の分解度の指標であり、澱粉分解物中の還元糖量をブドウ糖当量に換算し、当該ブドウ糖当量を、澱粉分解物の全固形分量で除して百分率で表した値(ブドウ糖当量/全固形分量×100)である。この際、澱粉分解物中の還元糖量は、レインエイノン法、ウィルシュテッターシューデル法、ベルトラン法、またはHPLC法で測定される(例えば、「澱粉糖関連工業分析法」(澱粉糖技術部会編、食品化学新聞社発行(平成3(1991)年11月1日発行))を参照)。なお、純粋なブドウ糖のD.E.は100となり、分解されていない澱粉(天然澱粉)のD.E.は0となる。 The dextrose equivalent (DE) of the starch hydrolyzate is preferably 20 or less, more preferably 15 or less, even more preferably 10 or less, and particularly preferably 5 or less. , more than 0 and less than or equal to 5. When the starch hydrolyzate has a dextrose equivalent of 20 or less, deterioration over time is less likely to occur, which is preferable. As a result, for example, the physical properties (filling suitability, heat-sealing property, jelly strength, flexibility, etc.) of a film (wet film) formed during the production of capsules and the physical properties of capsules (hardness, blocking resistance, appearance) are high. In addition, it is possible to obtain effects such as prevention of discoloration of the capsule from yellow to brown. In the present specification, "dextrose equivalent (D.E.)" is an index of the degree of starch decomposition, and the amount of reducing sugar in the starch decomposition product is converted to a glucose equivalent, and the glucose equivalent is converted to starch decomposition. It is a value expressed as a percentage (glucose equivalent/total solid content x 100) divided by the total solid content of the product. At this time, the amount of reducing sugars in the starch hydrolyzate is measured by the Reine Einone method, the Willstetter-Schudel method, the Bertrand method, or the HPLC method (for example, "Starch Sugar Related Industrial Analysis Method" (Starch Sugar Technical Committee Ed., published by Shokuhin Kagaku Shimbunsha (published on November 1, 1991))). In addition, pure glucose D.I. E. is 100, the D.O.D. of undegraded starch (native starch). E. becomes 0.
 これらのうち、澱粉類は、天然澱粉および加工澱粉からなる群から選択される少なくとも1種を含むことが好ましく、天然澱粉、エーテル化澱粉、澱粉分解物からなる群から選択される少なくとも1種を含むことがより好ましく、天然澱粉、エーテル化澱粉からなる群から選択される少なくとも1種を含むことがさらに好ましく、天然澱粉およびヒドロキシプロピル化澱粉からなる群から選択される少なくとも1種を含むことが特に好ましい。なお、上述の澱粉類は単独で用いても、2種以上を組み合わせて用いてもよい。 Among these, the starch preferably contains at least one selected from the group consisting of natural starch and modified starch, and at least one selected from the group consisting of natural starch, etherified starch, and starch hydrolyzate. More preferably, it contains at least one selected from the group consisting of native starch and etherified starch, and at least one selected from the group consisting of native starch and hydroxypropylated starch. Especially preferred. In addition, the above-mentioned starches may be used alone or in combination of two or more.
 澱粉類の粘度は、200mPa・s以下であることが好ましく、100mPa・s以下であることがより好ましく、50mPa・s以下であることがさらに好ましく、1~50mPa・sであることが特に好ましく、20~50mPa・sであることが最も好ましい。澱粉類の粘度が200mPa・s以下であると、カプセル剤皮組成物の粘度を低減することができることから好ましい。なお、本明細書において、「澱粉類の粘度」は、実施例に記載の方法で測定された平均値を意味する。 The viscosity of the starch is preferably 200 mPa s or less, more preferably 100 mPa s or less, even more preferably 50 mPa s or less, and particularly preferably 1 to 50 mPa s. Most preferably, it is 20 to 50 mPa·s. It is preferable that the viscosity of the starch is 200 mPa·s or less, since the viscosity of the capsule shell composition can be reduced. In addition, in this specification, the "viscosity of starches" means the average value measured by the method described in the Examples.
 澱粉類の含有量は、カプセル剤皮組成物の全質量に対して、3質量%以上であることが好ましく、8質量%以上であることがより好ましく、10質量%以上であることがさらに好ましく、15質量%以上であることが特に好ましく、19質量%以上であることが最も好ましい。また、澱粉類の含有量は、カプセル剤皮組成物の全質量に対して、40質量%以下であることが好ましく、30質量%以下であることがより好ましく、22質量%以下であることがさらに好ましく、い。一実施形態において、澱粉類の含有量は、カプセル剤皮組成物の全質量に対して、3~40質量%であることが好ましく、10~30質量%、10~25質量%であることがより好ましく、15~25質量%であることがさらに好ましい。澱粉類の含有量が3質量%以上であると、カプセル皮膜を好適に形成できることから好ましい。一方、澱粉類の含有量が40質量%以下であると、カプセル剤皮組成物への他の成分(例えば、イオタカラギーナン)の添加による物性調整がしやすいことから好ましい。 The starch content is preferably 3% by mass or more, more preferably 8% by mass or more, and even more preferably 10% by mass or more, relative to the total mass of the capsule shell composition. , is particularly preferably 15% by mass or more, and most preferably 19% by mass or more. The starch content is preferably 40% by mass or less, more preferably 30% by mass or less, and 22% by mass or less, relative to the total mass of the capsule shell composition. More preferably, yes. In one embodiment, the starch content is preferably 3 to 40% by mass, preferably 10 to 30% by mass, and 10 to 25% by mass, based on the total mass of the capsule shell composition. More preferably, 15 to 25% by mass is even more preferable. A starch content of 3% by mass or more is preferable because the capsule shell can be suitably formed. On the other hand, when the starch content is 40% by mass or less, it is preferable because the physical properties can be easily adjusted by adding other components (for example, iota carrageenan) to the capsule shell composition.
 [イオタカラギーナン]
 イオタ(ι)カラギーナンは、柔らかくて弾力性があり、離水の少ない透明度の高いゲルを形成できる。このため、イオタカラギーナンは、例えば、カプセル剤の製造時に形成されるフィルム(湿潤皮膜)のゼリー強度および柔軟性、カプセル剤の硬度および外観の少なくとも1つを向上させる機能等を有する。
[Iota carrageenan]
Iota (ι) carrageenan can form soft, elastic, highly transparent gels with low syneresis. Therefore, iota-carrageenan has the function of improving at least one of jelly strength and flexibility of a film (wet film) formed during production of capsules, hardness and appearance of capsules, and the like.
 イオタカラギーナンは、以下の構造式で表される直鎖構造の主鎖を有する。 Iota carrageenan has a main chain with a linear structure represented by the following structural formula.
Figure JPOXMLDOC01-appb-C000001
Figure JPOXMLDOC01-appb-C000001
 すなわち、イオタカラギーナンは、1つの硫酸エステル基を有するガラストースおよび1つの硫酸エステル基を有する3,6-アンヒドロガラクトースから構成される直鎖構造の主鎖を有する。なお、イオタカラギーナンは、主鎖の一部に、2つの硫酸エステル基を有するガラクトース、硫酸エステル基を有さない3,6-アンヒドロガラクトースを有していてもよいし、分岐鎖を有していてもよい。 That is, iota carrageenan has a linear main chain composed of glasstose having one sulfate group and 3,6-anhydrogalactose having one sulfate group. In addition, iota carrageenan may have galactose having two sulfate ester groups, 3,6-anhydrogalactose having no sulfate ester groups, or branched chains in a part of the main chain. may be
 イオタカラギーナンの粘度は、5000mPa・s以下であることが好ましく、4000mPa・s以下であることがより好ましく、500~4000mPa・sであることがさらに好ましく、1000~3500mPa・sであることが特に好ましい。イオタカラギーナンの粘度が5000mPa・s以下であると、カプセル剤皮組成物の粘度を低減することができることから好ましい。なお、本明細書において、「イオタカラギーナンの粘度」は、実施例に記載の方法で測定された平均値を意味する。 The viscosity of iota carrageenan is preferably 5000 mPa s or less, more preferably 4000 mPa s or less, still more preferably 500 to 4000 mPa s, particularly preferably 1000 to 3500 mPa s. . Iota-carrageenan having a viscosity of 5000 mPa·s or less is preferable because the viscosity of the capsule shell composition can be reduced. In the present specification, the "viscosity of iota carrageenan" means the average value measured by the method described in Examples.
 イオタカラギーナンの含有量は、カプセル剤皮組成物の全質量に対して、2質量%以上であり、3質量%以上であることが好ましく、4質量%以上であることがさらに好ましく、6質量%以上であることが特に好ましい。また、イオタカラギーナンの含有量は、カプセル剤皮組成物の全質量に対して、20質量%以下であることが好ましく、15質量%以下であることがより好ましく、10質量%以下であることがさらに好ましい。一実施形態において、イオタカラギーナンの含有量は、カプセル剤皮組成物の全質量に対して、2~20質量%であることが好ましく、3~20質量%であることがより好ましく、4~20質量%であることがさらに好ましく、4~15質量%であることが特に好ましく、4~10質量%であることがさらに好ましく、6~10質量%であることが最も好ましい。イオタカラギーナンの含有量が2質量%以上であると、カプセル剤の製造時に形成されるフィルム(湿潤皮膜)のゼリー強度および柔軟性、カプセル剤の硬度および外観の少なくとも1つを向上させうることから好ましい。他方、イオタカラギーナンの含有量が20質量%以下であると、カプセル剤皮組成物の粘度を低くできることから好ましい。 The content of iota carrageenan is 2% by mass or more, preferably 3% by mass or more, more preferably 4% by mass or more, and 6% by mass, relative to the total mass of the capsule shell composition. It is particularly preferable that it is above. The content of iota carrageenan is preferably 20% by mass or less, more preferably 15% by mass or less, and preferably 10% by mass or less, relative to the total mass of the capsule shell composition. More preferred. In one embodiment, the content of iota carrageenan is preferably 2 to 20% by mass, more preferably 3 to 20% by mass, more preferably 4 to 20% by mass, based on the total mass of the capsule shell composition. % by mass is more preferred, 4 to 15% by mass is particularly preferred, 4 to 10% by mass is more preferred, and 6 to 10% by mass is most preferred. When the content of iota carrageenan is 2% by mass or more, at least one of the jelly strength and flexibility of the film (wet film) formed during production of the capsule, and the hardness and appearance of the capsule can be improved. preferable. On the other hand, if the content of iota carrageenan is 20% by mass or less, the viscosity of the capsule shell composition can be lowered, which is preferable.
 なお、イオタカラギーナンは、Eucheuma Spinosum等を抽出等することで得ることができる。例えば、Eucheuma Spinosumを水洗し、粉砕、煮沸してイオタカラギーナンを抽出した後、濾過、単離・精製・脱水した後、乾燥、粉砕し、必要に応じて砂糖などを用いることでイオタカラギーナンを得ることができる。この際、イオタカラギーナンの単離・精製・脱水は、ゲルプレス法で行うことが好ましい。前記ゲルプレス法は、イオタカラギーナン抽出液を冷却してイオタカラギーナンをゲル化した後に加圧し脱水する方法であり、必要に応じて冷却ゲル化する前に塩化カリウム等の金属塩を添加してもよい。ゲルプレス法は、アルコール沈殿法(イオタカラギーナン抽出液をアルコールに添加してイオタカラギーナンを析出・沈殿させて回収する方法)等と比べて、精製の際にアミノ酸やタンパク質や比較的低分子の糖質等の不純物が混入しにくい。このため、ゲルプレス法は、メイラード反応、およびこれに伴うpH低下が起こりにくく、イオタカラギーナンの分解が生じにくいため、高品質のイオタカラギーナンを得ることができる。 In addition, iota carrageenan can be obtained by extracting Eucheuma Spinosum, etc. For example, Eucheuma Spinosum is washed with water, pulverized, and boiled to extract iota carrageenan, filtered, isolated, purified, dehydrated, dried, pulverized, and if necessary, sugar or the like is used to obtain iota carrageenan. be able to. At this time, isolation, purification and dehydration of iota carrageenan are preferably carried out by a gel press method. The gel press method is a method in which the iota carrageenan extract is cooled to gel the iota carrageenan, and then pressurized and dehydrated. If necessary, a metal salt such as potassium chloride may be added before cooling and gelling. . Compared to the alcohol precipitation method (a method in which the iota carrageenan extract is added to alcohol to precipitate and precipitate the iota carrageenan and recover it), the gel press method does not allow amino acids, proteins, and relatively low-molecular-weight carbohydrates to be extracted during purification. It is difficult for impurities such as Therefore, the gel press method is less likely to cause the Maillard reaction and accompanying pH reduction, and thus less likely to cause the decomposition of iota carrageenan, so that high-quality iota carrageenan can be obtained.
 [ガム類]
 ガム類は、カプセル剤皮組成物の粘度を低下させる機能、カプセル剤の製造時に形成されるフィルム(湿潤皮膜)の柔軟性を向上させる機能等を有する。なお、ガム類は、上記イオタカラギーナンと相乗効果を示しうる。例えば、ガム類とイオタカラギーナンとは、二重らせん構造を形成する。当該二重らせん構造は結晶領域および非晶領域を有する剛性な骨格であり、湿潤皮膜およびカプセル剤のカプセル皮膜中で安定に存在しうる。その結果、イオタカラギーナンによる湿潤皮膜のゼリー強度および柔軟性、カプセル剤の硬度および外観の向上効果を高める、イオタカラギーナンの添加によるカプセル剤皮組成物の粘度上昇を抑制する、イオタカラギーナンの分解を防止する等のうち少なくとも1つの効果をさらに奏しうる。
[Gums]
Gums have a function of reducing the viscosity of the capsule shell composition, a function of improving the flexibility of the film (wet film) formed during the manufacture of the capsule, and the like. Gums may exhibit a synergistic effect with the iota carrageenan. For example, gums and iota carrageenan form a double helix structure. The double helix structure is a rigid skeleton having crystalline and amorphous regions, and can stably exist in the wet film and the capsule shell of the capsule. As a result, iota carrageenan enhances the jelly strength and flexibility of the wet film, the hardness and appearance of the capsule, suppresses the increase in viscosity of the capsule shell composition due to the addition of iota carrageenan, and prevents the decomposition of iota carrageenan. At least one effect of performing, etc. can be further exhibited.
 ガム類は、アラビアガム、グァーガム、ローカストビーンガム、ジェランガム、キサンタンガム、およびタマリンドガムからなる群から選択される1種以上であることが好ましく、アラビアガム、グァーガム、およびジェランガムからなる群から選択される1種以上であることがより好ましく、得られる湿潤皮膜のゼリー強度、柔軟性、得られるカプセル剤の硬度等が向上しうる観点から、アラビアガムおよびジェランガムからなる群から選択される1種以上であることがさらに好ましく、アラビアガムを含むことが特に好ましい。なお、ガム類は単独で用いても、2種以上を組み合わせて用いてもよい。 The gums are preferably one or more selected from the group consisting of gum arabic, guar gum, locust bean gum, gellan gum, xanthan gum, and tamarind gum, and are selected from the group consisting of gum arabic, guar gum, and gellan gum. It is more preferably one or more, and one or more selected from the group consisting of gum arabic and gellan gum from the viewpoint of improving the jelly strength and flexibility of the resulting wet film and the hardness of the resulting capsule. More preferably, it contains gum arabic. In addition, gums may be used individually or may be used in combination of 2 or more types.
 なお、アラビアガムは、多糖類を主成分とし、アラビノガラクタン、アラビノガラクタンプロテイン、および糖タンパク質等を含む。
 グァーガムは、直鎖状に結合したマンノース2分子に1分子のガラクトースの側鎖をもつ多糖類である。この際、グァーガムはグァーガム誘導体であってもよく、前記グァーガム誘導体としては、ヒドロキシプロピルグァーガム、カチオン化グァーガム、グァーガム酵素分解物が挙げられる。
 ローカストビーンガムは、直鎖状に結合したマンノース4分子に1分子のガラクトースの側鎖をもつ多糖類である。
 ジェランガムとしては、高アシルジェランガム、低アシルジェランガムが挙げられる。前記高アシルジェランガムは、ネイティブ型ジェランガムとも呼ばれ、構成糖(主にグルコース)にアシル基が結合した構造を有する。前記低アシルジェランガムは、脱アシル型ジェランガムとも呼ばれ、高アシルジェランガムを脱アシル化して得られる。これらのうち、ジェランガムは、ゲル化温度が低くカプセル製造に適している観点から、低アシルジェランガムであることが好ましい。
 キサンタンガムは、グルコース2分子、マンノース2分子、およびグルクロン酸の繰り返し単位構造を有する。
 タマリンドガムは、主鎖がグルコースを含み、側鎖がキシロースおよびガラクトースを含む、キシログルカンと呼ばれる構造を有する多糖類である。
Gum arabic is mainly composed of polysaccharides and includes arabinogalactan, arabinogalactan protein, glycoprotein, and the like.
Guar gum is a polysaccharide having two molecules of mannose linked in a linear chain and one molecule of galactose as a side chain. At this time, the guar gum may be a guar gum derivative, and examples of the guar gum derivative include hydroxypropyl guar gum, cationized guar gum, and guar gum enzymatic decomposition products.
Locust bean gum is a polysaccharide having 4 molecules of mannose linked in a straight chain and a side chain of 1 molecule of galactose.
Gellan gum includes high acyl gellan gum and low acyl gellan gum. The high-acyl gellan gum is also called native gellan gum, and has a structure in which acyl groups are bound to constituent sugars (mainly glucose). The low acyl gellan gum is also called deacylated gellan gum, and is obtained by deacylating high acyl gellan gum. Among these, gellan gum is preferably low acyl gellan gum from the viewpoint of its low gelation temperature and suitability for capsule production.
Xanthan gum has a repeating unit structure of two molecules of glucose, two molecules of mannose, and glucuronic acid.
Tamarind gum is a polysaccharide with a structure called xyloglucan, which contains glucose in the main chain and xylose and galactose in the side chains.
 ガム類の含有量は、カプセル剤皮組成物の全質量に対して、0.3~14質量%であり、0.3~7.5質量%であることが好ましく、1~7.5質量%であることがより好ましく、1~4質量%であることがさらに好ましい。ガム類の含有量が上記範囲であると、カプセル剤皮組成物の粘度を低くできることから好ましい。また、カプセル剤の製造時に形成されるフィルム(湿潤皮膜)の物性(充填適正、ヒートシール性、ゼリー強度、柔軟性等)およびカプセル剤の物性(硬度、ブロッキング耐性、外観)の少なくとも1つを向上させうることから好ましい。 The content of gums is 0.3 to 14% by mass, preferably 0.3 to 7.5% by mass, and 1 to 7.5% by mass, relative to the total mass of the capsule shell composition. %, more preferably 1 to 4% by mass. It is preferable that the content of the gums is within the above range, since the viscosity of the capsule shell composition can be lowered. In addition, at least one of the physical properties of the film (wet film) formed during capsule production (filling suitability, heat-sealing property, jelly strength, flexibility, etc.) and the physical properties of the capsule (hardness, blocking resistance, appearance) It is preferable because it can be improved.
 [澱粉類、イオタカラギーナン、ガム類の含有量]
 一実施形態において、イオタカラギーナンに対する澱粉類の含有量比(澱粉類の含有量(質量%)/イオタカラギーナンの含有量(質量%))は、1~20であることが好ましく、1.2~10であることがより好ましく、1.2~5であることがさらに好ましく、2~5であることが特に好ましい。
 一実施形態において、ガム類に対する澱粉類の含有量比(澱粉類の含有量(質量%)/ガム類の含有量(質量%))は、1~75であることが好ましく、1~50であることがより好ましく、2~50であることがさらに好ましく、2~40であることが特に好ましく、5~30であることが最も好ましい。
 一実施形態において、ガム類に対するイオタカラギーナンの含有量比(イオタカラギーナンの含有量(質量%)/ガム類の含有量(質量%))は、0.1~30であることが好ましく、0.5~15であることがより好ましく、1~25であることがさらに好ましく、2~25であることが特に好ましく、2~12であることが最も好ましい。
[Contents of starches, iota carrageenan, gums]
In one embodiment, the content ratio of starches to iota carrageenan (content of starches (% by mass)/content of iota carrageenan (% by mass)) is preferably 1 to 20, preferably 1.2 to 10 is more preferred, 1.2 to 5 is even more preferred, and 2 to 5 is particularly preferred.
In one embodiment, the content ratio of starches to gums (starch content (mass%)/gums content (mass%)) is preferably 1 to 75, preferably 1 to 50. It is more preferably 1, more preferably 2 to 50, particularly preferably 2 to 40, and most preferably 5 to 30.
In one embodiment, the content ratio of iota carrageenan to gums (content of iota carrageenan (% by mass)/content of gums (% by mass)) is preferably 0.1 to 30. It is more preferably from 5 to 15, even more preferably from 1 to 25, particularly preferably from 2 to 25, and most preferably from 2 to 12.
 一実施形態において、澱粉類およびイオタカラギーナンの総含有量は、カプセル剤皮組成物の全質量に対して、5~40質量%であることが好ましく、10~40質量%であることがより好ましく、22~40質量%であることがさらに好ましく、26~40質量%であることが特に好ましい。
 一実施形態において、澱粉類およびガム類の総含有量は、カプセル剤皮組成物の全質量に対して、3.5~40質量%であることが好ましく、5~35質量%であることがより好ましく、15~30質量%であることがさら好ましく、15~25質量%であることが特に好ましく、21~25質量%であることが最も好ましい。
 一実施形態において、イオタカラギーナンおよびガム類の総含有量は、カプセル剤皮組成物の全質量に対して、2.5~30質量%であることが好ましく、2.5~20質量%であることがより好ましく、2.5~15質量%であることがさらに好ましく、2.5~10質量%であることが特に好ましい。
In one embodiment, the total content of starches and iota carrageenan is preferably 5 to 40% by mass, more preferably 10 to 40% by mass, based on the total mass of the capsule shell composition. , more preferably 22 to 40% by mass, particularly preferably 26 to 40% by mass.
In one embodiment, the total content of starches and gums is preferably 3.5 to 40% by mass, preferably 5 to 35% by mass, based on the total mass of the capsule shell composition. It is more preferably 15 to 30% by mass, particularly preferably 15 to 25% by mass, and most preferably 21 to 25% by mass.
In one embodiment, the total content of iota carrageenan and gums is preferably 2.5 to 30% by weight, preferably 2.5 to 20% by weight, based on the total weight of the capsule shell composition. is more preferable, 2.5 to 15% by mass is more preferable, and 2.5 to 10% by mass is particularly preferable.
 [アルギン酸エステル]
 一実施形態において、カプセル剤皮組成物は、アルギン酸エステルをさらに含むことが好ましい。
[Alginate ester]
In one embodiment, the capsule shell composition preferably further comprises alginate.
 アルギン酸エステルは、カプセル剤皮組成物の粘度の上昇を抑制しつつ、カプセル剤の製造時に形成されるフィルム(湿潤皮膜)のゼリー強度、カプセル剤の物性の硬度を向上させることができる。このような効果が得られる理由は明らかではないが、例えば、アルギン酸エステルとガム類との相乗効果が考えられる。具体的には、アルギン酸エステルがガム類の構成成分であるタンパク質に作用することで、ガム類が有するイオタカラギーナンの添加によるカプセル剤皮組成物の粘度上昇抑制効果をより向上させることが考えられる。 The alginate can improve the jelly strength of the film (wet film) formed during capsule production and the hardness of the physical properties of the capsule while suppressing the increase in the viscosity of the capsule shell composition. Although the reason why such an effect is obtained is not clear, for example, a synergistic effect between alginic acid ester and gums is considered. Specifically, it is conceivable that the action of alginate on proteins, which are constituents of gums, will further improve the effect of suppressing increases in the viscosity of capsule shell compositions due to the addition of iota-carrageenan contained in gums.
 アルギン酸エステルは、2種のウロン酸(β-D-マンヌロン酸(M)およびα-L-グルロン酸(G))が重合した直鎖状の多糖類であるアルギン酸が有するカルボキシ基に、プロピレングリコールがエステル結合した構造を有する。アルギン酸エステルは、親水性のアルギン酸部および親油性のプロピレングリコール部を有するため界面活性効果を有する。 Alginic acid ester is a linear polysaccharide polymerized from two types of uronic acid (β-D-mannuronic acid (M) and α-L-guluronic acid (G)). has an ester-bonded structure. Alginate has a surface active effect because it has a hydrophilic alginic acid portion and a lipophilic propylene glycol portion.
 アルギン酸エステルの含有量は、カプセル剤皮組成物の全質量に対して、0.001質量%以上であり、0.01質量%以上であることが好ましく、0.03質量%以上であることがさらに好ましく、0.3質量%以上であることが特に好ましい。また、アルギン酸エステルの含有量は、カプセル剤皮組成物の全質量に対して、10質量%以下であることが好ましく、5質量%以下であることがより好ましく、0.75質量%以下であることが特に好ましい。一実施形態において、アルギン酸エステルの含有量は、カプセル剤皮組成物の全質量に対して、0.001~10質量%であることが好ましく、0.001~5質量%であることがより好ましく、0.01~5質量%であることがさらに好ましく、0.03~0.75質量%であることが特に好ましい。アルギン酸エステルの含有量が上記範囲であると、カプセル剤皮組成物の粘度の上昇を抑制しつつ、カプセル剤の製造時に形成されるフィルム(湿潤皮膜)のゼリー強度、カプセル剤の物性の硬度を向上させることができる。 The alginate content is 0.001% by mass or more, preferably 0.01% by mass or more, and preferably 0.03% by mass or more, relative to the total mass of the capsule shell composition. More preferably, it is particularly preferably 0.3% by mass or more. The alginate content is preferably 10% by mass or less, more preferably 5% by mass or less, and 0.75% by mass or less, relative to the total mass of the capsule shell composition. is particularly preferred. In one embodiment, the alginate content is preferably 0.001 to 10% by mass, more preferably 0.001 to 5% by mass, relative to the total mass of the capsule shell composition. , more preferably 0.01 to 5% by mass, and particularly preferably 0.03 to 0.75% by mass. When the content of the alginate is within the above range, the jelly strength of the film (wet film) formed during the production of the capsules and the hardness of the physical properties of the capsules are improved while suppressing an increase in the viscosity of the capsule shell composition. can be improved.
 アルギン酸エステルに対するガム類の含有量比(ガム類の含有量(質量%)/アルギン酸エステルの含有量(質量%))は、0.01~100であることが好ましく、0.1~50であることがより好ましく、0.5~20であることがさらに好ましく、3~20であることが特に好ましい。 The content ratio of gums to alginate (content of gums (% by mass)/content of alginate (% by mass)) is preferably 0.01 to 100, and 0.1 to 50. is more preferred, 0.5 to 20 is even more preferred, and 3 to 20 is particularly preferred.
 [可塑剤]
 一実施形態において、カプセル剤皮組成物は、可塑剤をさらに含むことが好ましい。
[Plasticizer]
In one embodiment, the capsule shell composition preferably further comprises a plasticizer.
 可塑剤は、カプセル剤の製造時に形成されるフィルム(湿潤皮膜)に柔軟性を付与する機能を有する。 A plasticizer has the function of imparting flexibility to the film (wet film) formed during the production of capsules.
 可塑剤としては、特に制限されないが、グリセリン、ソルビトール、マルチトール、エチレングリコール、プロピレングリコール等の多価アルコール;ヒドロキシメチルセルロース(HPMC)、ヒドロキシプロピルセルロース(HPC)、メチルセルロース(MC)、カルボキシメチルセルロース(CMC)等のセルロース誘導体等が挙げられる。これらのうち、可塑剤は、多価アルコールを含むことが好ましく、グリセリンを含むことがより好ましい。これらの可塑剤は単独で用いても、2種以上を組み合わせて用いてもよい。 Plasticizers include, but are not limited to, polyhydric alcohols such as glycerin, sorbitol, maltitol, ethylene glycol, propylene glycol; hydroxymethylcellulose (HPMC), hydroxypropylcellulose (HPC), methylcellulose (MC), carboxymethylcellulose (CMC); ) and other cellulose derivatives. Among these, the plasticizer preferably contains a polyhydric alcohol, and more preferably contains glycerin. These plasticizers may be used alone or in combination of two or more.
 可塑剤の含有量は、カプセル剤皮組成物の全質量に対して、1~50質量%であることが好ましく、5~30質量%であることがより好ましく、5~25質量%であることがさらに好ましい。可塑剤の含有量が上記範囲であると、湿潤皮膜の柔軟性が好適なものとなることから好ましい。 The content of the plasticizer is preferably 1 to 50% by mass, more preferably 5 to 30% by mass, and 5 to 25% by mass, relative to the total mass of the capsule shell composition. is more preferred. It is preferable that the content of the plasticizer is within the above range, since the flexibility of the wet film becomes suitable.
 [ゼラチン]
 一実施形態において、カプセル剤皮組成物は、ゼラチンをさらに含んでもよい。カプセル剤皮組成物がゼラチンを含むことで、カプセル剤皮組成物の粘度および流動性、形成されるカプセル皮膜の強度、ヒートシール性、割れ耐性等を向上させることができる。
[gelatin]
In one embodiment, the capsule shell composition may further comprise gelatin. By including gelatin in the capsule shell composition, it is possible to improve the viscosity and flowability of the capsule shell composition, the strength of the formed capsule shell, the heat-sealing property, the resistance to cracking, and the like.
 ゼラチンとしては、特に限定されないが、豚ゼラチン、牛ゼラチン、魚ゼラチン、またはゼラチン誘導体等が挙げられる。前記ゼラチン誘導体としては、例えば、コハク化ゼラチン、ゼラチン加水分解物、架橋型ゼラチン等が挙げられる。これらのゼラチンは、単独で用いても、2種以上を組み合わせて用いてもよい。なお、例えば、魚ゼラチンまたはその誘導体を用いることで、例えば、宗教、菜食主義、アレルギー等の観点から、動物性コラーゲンの摂取が困難な場合でも、摂取できる場合がある。 Examples of gelatin include, but are not limited to, pig gelatin, bovine gelatin, fish gelatin, gelatin derivatives, and the like. Examples of the gelatin derivatives include succinated gelatin, gelatin hydrolysates, and crosslinked gelatin. These gelatins may be used alone or in combination of two or more. For example, by using fish gelatin or a derivative thereof, it may be possible to ingest animal collagen even in cases where it is difficult to ingest animal collagen from the viewpoint of religion, vegetarianism, allergies, or the like.
 ゼラチンの含有量は、カプセル剤皮組成物の全質量に対して、40質量%以下であることが好ましく、30質量%以下であることがより好ましく、1~20質量%であることがさらに好ましい。 The gelatin content is preferably 40% by mass or less, more preferably 30% by mass or less, and even more preferably 1 to 20% by mass, relative to the total mass of the capsule shell composition. .
 [溶媒]
 一実施形態において、カプセル剤皮組成物は、溶媒を含むことが好ましい。カプセル剤皮組成物が溶媒を含むことで、カプセル剤皮組成物の粘度調整等をすることができる。
[solvent]
In one embodiment, the capsule shell composition preferably contains a solvent. By including a solvent in the capsule shell composition, the viscosity of the capsule shell composition can be adjusted.
 溶媒の具体例としては、水または有機溶媒が挙げられる。 Specific examples of solvents include water and organic solvents.
 前記有機溶媒としては、特に制限されないが、エタノール、イソプロピルアルコール、アセトン、酪酸エチル等が挙げられる。 The organic solvent is not particularly limited, but includes ethanol, isopropyl alcohol, acetone, ethyl butyrate, and the like.
 これらのうち、溶媒は、水を含むことが好ましい。なお、上述の溶媒は単独で用いても、2種以上を組み合わせて用いてもよい。 Among these, the solvent preferably contains water. In addition, the above-mentioned solvent may be used independently or may be used in combination of 2 or more types.
 溶媒の含有量は、カプセル剤皮組成物の全質量に対して、20~90質量%であることが好ましく、30~80質量%であることがより好ましく、40~70質量%であることがさらに好ましく、50~60質量%であることが特に好ましい。 The content of the solvent is preferably 20 to 90% by mass, more preferably 30 to 80% by mass, and 40 to 70% by mass, based on the total mass of the capsule shell composition. More preferably, it is particularly preferably 50 to 60% by mass.
 [添加剤]
 一実施形態において、カプセル剤皮組成物は、添加剤を含んでいてもよい。
[Additive]
In one embodiment, the capsule shell composition may contain additives.
 当該添加剤としては、他の増粘剤、pH調整剤、金属封鎖剤、皮膜着色剤、矯味剤、甘味剤、保存剤、香料等が挙げられる。 Such additives include other thickeners, pH adjusters, sequestering agents, film coloring agents, corrigents, sweeteners, preservatives, flavoring agents, and the like.
 他の増粘剤は、イオタカラギーナン、ガム類、ゼラチン、アルギン酸エステル以外の増粘剤を意味する。当該他の増粘剤としては、特に制限されないが、カッパ(κ)カラギーナン、ラムダ(λ)カラギーナン、プルラン、寒天、アルギン酸、アルギン酸ナトリウム等が挙げられる。これらの他の増粘剤は、単独で用いても、2種以上を組み合わせて用いてもよい。 "Other thickeners" means thickeners other than iota carrageenan, gums, gelatin, and alginate. The other thickening agents include, but are not limited to, kappa (κ) carrageenan, lambda (λ) carrageenan, pullulan, agar, alginic acid, sodium alginate, and the like. These other thickening agents may be used alone or in combination of two or more.
 なお、カッパカラギーナンは、1つの硫酸エステル基を有するガラクトースおよび硫酸エステル基を有さない3,6-アンヒドロガラクトースから構成される直鎖構造の主鎖を有する。なお、カッパカラギーナンは、主鎖の一部に、2つの硫酸エステル基を有するガラクトース、硫酸エステル基を有する3,6-アンヒドロガラクトースを有していてもよいし、分岐鎖を有していてもよい。 Kappa-carrageenan has a linear main chain composed of galactose having one sulfate ester group and 3,6-anhydrogalactose having no sulfate ester group. In addition, kappa carrageenan may have galactose having two sulfate ester groups, 3,6-anhydrogalactose having sulfate ester groups in part of the main chain, or may have a branched chain. good too.
 また、ラムダカラギーナンは、2つの硫酸エステル基を有するガラクトースおよび1つの硫酸エステル基を有するガラクトースから構成される直鎖構造の主鎖を有する。なお、ラムダカラギーナンは、主鎖の一部に、硫酸エステル基を有する3,6-アンヒドロガラクトース、硫酸エステル基を有さない3,6-アンヒドロガラクトースを有していてもよいし、分岐鎖を有していてもよい。 In addition, lambda carrageenan has a main chain with a linear structure composed of galactose with two sulfate ester groups and galactose with one sulfate ester group. Lambda carrageenan may have 3,6-anhydrogalactose having a sulfate ester group, 3,6-anhydrogalactose having no sulfate ester group, or branched It may have chains.
 pH調整剤としては、特に制限されないが、塩酸、硫酸、硝酸等の酸;水酸化ナトリウム、水酸化カリウム等の塩基;リン酸塩緩衝剤、トリス緩衝剤等の緩衝剤等が挙げられる。これらのpH調整剤は単独で用いても、2種以上を組み合わせて用いてもよい。なお、好ましい一実施形態において、カプセル剤皮組成物は、緩衝剤を含まないことが好ましく、リン酸塩緩衝剤を含まないことがより好ましい。 The pH adjuster is not particularly limited, but includes acids such as hydrochloric acid, sulfuric acid, and nitric acid; bases such as sodium hydroxide and potassium hydroxide; buffers such as phosphate buffers and Tris buffers. These pH adjusters may be used alone or in combination of two or more. In one preferred embodiment, the capsule shell composition preferably does not contain a buffering agent, and more preferably does not contain a phosphate buffering agent.
 また、金属封鎖材としては、クエン酸、酒石酸、乳酸、リン酸、酢酸、グルコン酸、エチレンジアミン四酢酸、メタリン酸、これらの塩;グリシン等が挙げられる。 In addition, sequestering agents include citric acid, tartaric acid, lactic acid, phosphoric acid, acetic acid, gluconic acid, ethylenediaminetetraacetic acid, metaphosphoric acid, salts thereof; glycine, and the like.
 これらの添加剤は、単独で用いても、2種以上を組み合わせて用いてもよい。 These additives may be used alone or in combination of two or more.
 [カプセル剤皮組成物の製造方法]
 カプセル剤皮組成物の製造方法は、特に制限されず、公知の方法により製造することができる。例えば、溶媒中に、澱粉、イオタカラギーナン、ガム類、および必要に応じてアルギン酸エステル、可塑剤、ゼラチン、添加剤を添加し、得られる懸濁液を加熱して溶解することでカプセル剤皮組成物を製造することができる。
[Method for producing capsule shell composition]
The method for producing the capsule shell composition is not particularly limited, and it can be produced by a known method. For example, starch, iota carrageenan, gums, and if necessary, alginate, plasticizer, gelatin, and additives are added to a solvent, and the resulting suspension is heated and dissolved to form a capsule shell composition. can manufacture things.
 2 カプセル剤
 本発明の一形態によれば、カプセル剤が提供される。前記カプセル剤は、内容物と、カプセル皮膜と、を含む。この際、カプセル皮膜が、上述のカプセル剤皮組成物を用いて形成される。
2 Capsules According to one aspect of the present invention, capsules are provided. The capsule includes contents and a capsule shell. At this time, a capsule shell is formed using the capsule shell composition described above.
 また、本発明の別の一形態によれば、内容物と、澱粉類、イオタカラギーナン、およびガム類を含む、カプセル皮膜と、を含むカプセル剤が提供される。この際、カプセル剤の硬度は15kg以上である。なお、前記カプセル皮膜は、アルギン酸エステル、可塑剤、ゼラチン、溶媒、添加剤の少なくとも1つをさらに含むことができる。 In addition, according to another aspect of the present invention, there is provided a capsule containing contents and a capsule shell containing starches, iota carrageenan, and gums. At this time, the capsule has a hardness of 15 kg or more. The capsule shell may further contain at least one of alginate, plasticizer, gelatin, solvent and additive.
 [内容物]
 内容物は、特に制限されず、有効成分および添加剤が挙げられる。
[Contents]
Contents are not particularly limited, and include active ingredients and additives.
 前記有効成分としては、特に制限されないが、催眠薬、向精神薬、抗てんかん薬パーキンソン症候群治療薬、鎮痛薬、アルツハイマー病治療薬、抗アレルギー薬、強心薬、抗不整脈薬、抗狭心症薬、抗高血圧症薬、抗高脂血症薬、利尿薬、去痰薬、抗喘息薬、制酸薬、消化性潰瘍治療薬、抗血栓薬、血栓溶解薬、抗炎症薬痛風治療薬、骨粗しょう症治療薬、慢性関節リウマチ治療薬糖尿病治療薬、抗癌薬、抗生物質、抗真菌薬、免疫抑制薬等の疾患の治療薬;ケイヒ、シャクヤク、キョウニン、トウニン、カンゾウ、オウバク、チンピ、トウヒ、セネガ、チョウジ、トウキ、ゲンチアナ、リュウタン、センブリ、ジオウ、ジギタリス、カノコソウ、キキョウ、アロエ、ハンゲ、ウコン、ショウキョウ等の生薬;葛根湯、安中散、五苓散、小青竜湯、当帰芍薬散、麻黄湯等の漢方薬;ビタミン類、ミネラル類、コラーゲン、コエンザイムQ10、DHA、EPA、ルテイン、ブルーベリー、プラセンタ、大豆イソフラボン、乳酸菌、ビフィズス菌等の健康増進用成分;カリオフィレン、メントール、リモネン、セスキテルペン、バニリン等の芳香成分等が挙げられる。これらの有効成分は、単独で用いても、2種以上を組み合わせて用いてもよい。 Examples of the active ingredient include, but are not limited to, hypnotics, psychotropic drugs, antiepileptic drugs, antiparkinsonian drugs, analgesics, therapeutic drugs for Alzheimer's disease, antiallergic drugs, cardiotonic drugs, antiarrhythmic drugs, and antianginal drugs. , antihypertensive, antihyperlipidemic, diuretic, expectorant, antiasthmatic, antacid, peptic ulcer, antithrombotic, thrombolytic, anti-inflammatory, antigout, osteoporosis Rheumatoid arthritis therapeutic drugs Diabetes therapeutic drugs Anticancer drugs Antibiotics Antifungal drugs Immunosuppressive drugs; Crude drugs such as senega, clove, angelica gentian, gentian, ryutan, assembly, rhubarb, digitalis, valerian, bellflower, aloe, hange, turmeric, ginger; Herbal medicines such as shakuyakusan and maoto; vitamins, minerals, collagen, coenzyme Q10, DHA, EPA, lutein, blueberry, placenta, soybean isoflavone, lactic acid bacteria, bifidobacteria, and other health-promoting ingredients; caryophyllene, menthol, limonene, Aroma components such as sesquiterpene and vanillin are included. These active ingredients may be used alone or in combination of two or more.
 前記添加剤としては、特に制限されないが、賦形剤、着色剤、マスキング剤、甘味料、酸化防止剤、保存料、滑沢剤、香料等が挙げられる。これらの添加剤は、単独で用いても、2種以上を組み合わせて用いてもよい。 The additives include, but are not particularly limited to, excipients, coloring agents, masking agents, sweeteners, antioxidants, preservatives, lubricants, flavoring agents, and the like. These additives may be used alone or in combination of two or more.
 内容物の総質量は、カプセル剤の全質量に対して、40~90質量%であることが好ましく、50~80質量%であることがより好ましい。 The total mass of the contents is preferably 40-90% by mass, more preferably 50-80% by mass, relative to the total mass of the capsule.
 [カプセル皮膜]
 カプセル皮膜は、カプセル剤皮組成物を用いて形成される。一実施形態において、カプセル皮膜は、澱粉類、イオタカラギーナン、およびガム類を含む。前記カプセル皮膜は、アルギン酸エステル、可塑剤、ゼラチン、溶媒、添加剤の少なくとも1つをさらに含んでいてもよい。
[Capsule membrane]
A capsule shell is formed using a capsule shell composition. In one embodiment, the capsule shell comprises starches, iota carrageenan, and gums. The capsule shell may further contain at least one of alginate, plasticizer, gelatin, solvent, and additives.
 なお、カプセル皮膜においても、ゼラチンを含まないことが好ましい。また、カプセル皮膜は、リン酸緩衝剤を含まないことが好ましい。 In addition, it is preferable that the capsule shell does not contain gelatin. Moreover, it is preferable that the capsule shell does not contain a phosphate buffer.
 カプセル皮膜の膜厚は、200μm以上であることが好ましく、250~800μmであることがより好ましく、250~500μmであることがさらに好ましい。なお、カプセル皮膜の膜厚とは、カプセル皮膜の膜厚は、デジタルマイクロスコープ(例えば、(株)キーエンス製の商品名;VHX-900、10μmの校正スケールを使用)を用いて測定することができる。 The film thickness of the capsule shell is preferably 200 μm or more, more preferably 250 to 800 μm, even more preferably 250 to 500 μm. The film thickness of the capsule film can be measured using a digital microscope (for example, trade name VHX-900 manufactured by Keyence Corporation, using a 10 μm calibration scale). can.
 カプセル皮膜の総質量は、カプセル剤の全質量に対して、10~60質量%であることが好ましく、20~50質量%であることがより好ましい。 The total mass of the capsule shell is preferably 10-60% by mass, more preferably 20-50% by mass, relative to the total mass of the capsule.
 一実施形態において、カプセル皮膜中のイオタカラギーナンに対する澱粉類の含有量比(澱粉類の含有量(質量%)/イオタカラギーナンの含有量(質量%))は、1~20であることが好ましく、1.2~10であることがより好ましく、1.2~5であることがさらに好ましく、2~5であることが特に好ましい。
 一実施形態において、カプセル皮膜中のガム類に対する澱粉類の含有量比(澱粉類の含有量(質量%)/ガム類の含有量(質量%))は、1~75であることが好ましく、1~50であることがより好ましく、2~50であることがさらに好ましく、2~30であることが特に好ましく、5~30であることが最も好ましい。
 一実施形態において、カプセル皮膜中のガム類に対するイオタカラギーナンの含有量比(イオタカラギーナンの含有量(質量%)/ガム類の含有量(質量%))は、0.1~30であることが好ましく、0.5~15であることがより好ましく、1~25であることがさらに好ましく、2~25であることが特に好ましく、2~12であることが最も好ましい。
 なお、カプセル皮膜中の澱粉類の含有量(質量%)、イオタカラギーナンの含有量(質量%)、およびガム類の含有量(質量%)は、カプセル皮膜100質量%に対する各成分の含有量を意味する。また、各含有量比は、カプセル剤皮組成物における各含有量比に対応しうる。
In one embodiment, the content ratio of starch to iota carrageenan in the capsule shell (starch content (mass%)/iota carrageenan content (mass%)) is preferably 1 to 20, It is more preferably from 1.2 to 10, even more preferably from 1.2 to 5, and particularly preferably from 2 to 5.
In one embodiment, the content ratio of starches to gums in the capsule shell (starch content (mass%) / gum content (mass%)) is preferably 1 to 75, It is more preferably from 1 to 50, even more preferably from 2 to 50, particularly preferably from 2 to 30, and most preferably from 5 to 30.
In one embodiment, the content ratio of iota-carrageenan to gums in the capsule shell (iota-carrageenan content (% by mass)/gum content (% by mass)) is 0.1 to 30. It is preferably from 0.5 to 15, even more preferably from 1 to 25, particularly preferably from 2 to 25, and most preferably from 2 to 12.
The starch content (% by mass), the iota carrageenan content (% by mass), and the gum content (% by mass) in the capsule shell are the contents of each component with respect to 100% by mass of the capsule shell. means. Moreover, each content ratio can correspond to each content ratio in the capsule shell composition.
 [カプセル剤の構成]
 カプセル剤の形状は、特に制限されないが、球状、楕円体状、三角状、ひし形状、直方体状、長方体状等が挙げられる。
[Configuration of Capsule]
The shape of the capsule is not particularly limited, but may be spherical, ellipsoidal, triangular, rhomboidal, rectangular parallelepiped, rectangular parallelepiped, or the like.
 一実施形態において、カプセル剤は、軟カプセル剤であることが好ましい。軟カプセル剤であることにより、油分の多い液状の有効成分を製剤化できる、カプセル形状の自由度が大きい、カプセル表面に製品名を印刷することができる等の効果が得られうる。 In one embodiment, the capsule is preferably a soft capsule. By being a soft capsule, it is possible to obtain effects such as the ability to formulate a liquid active ingredient with a large amount of oil, a high degree of freedom in the shape of the capsule, and the ability to print the product name on the capsule surface.
 カプセル剤の硬度は、10kg以上であることが好ましく、15kg以上であることがより好ましく、20kg以上であることがさらに好ましく、22kg以上であることが特に好ましく、24kg以上、25kg以上であることが最も好ましい。なお、カプセル剤の硬度の上限値としては、例えば、40kg以下であることが好ましく、35kg以下であることがより好ましく、30kg以下であることがさらに好ましい。カプセル剤の硬度が高いことにより、保管時および流通時にカプセル剤の変形を抑制することができる。 The hardness of the capsule is preferably 10 kg or more, more preferably 15 kg or more, still more preferably 20 kg or more, particularly preferably 22 kg or more, and preferably 24 kg or more and 25 kg or more. Most preferred. The upper limit of hardness of the capsule is, for example, preferably 40 kg or less, more preferably 35 kg or less, and even more preferably 30 kg or less. Due to the high hardness of the capsule, deformation of the capsule can be suppressed during storage and distribution.
 3 カプセル剤の製造方法
 本発明の一形態によれば、カプセル剤の製造方法が提供される。カプセル剤の製造方法としては、特に制限されないが、有効成分を含む内容液を、上述のカプセル剤皮組成物に充填する充填工程と、得られた充填物を乾燥する乾燥工程を含む。
3 Method for producing capsules According to one aspect of the present invention, a method for producing capsules is provided. The method for producing capsules is not particularly limited, but includes a filling step of filling the capsule shell composition described above with a content liquid containing an active ingredient, and a drying step of drying the resulting filling.
 [充填工程]
 充填工程は、有効成分を含む内容液を、上述のカプセル剤皮組成物に充填する工程である。
[Filling process]
The filling step is a step of filling the capsule shell composition described above with a content liquid containing an active ingredient.
 内容液は、有効成分を含む。その他、添加剤をさらに含んでいてもよい。前記有効成分および添加剤は上述のとおりである。 The content liquid contains active ingredients. In addition, additives may be further included. Said active ingredients and additives are as described above.
 また、カプセル剤皮組成物は上述のとおりである。 In addition, the capsule shell composition is as described above.
 充填方法は、特に制限されないが、抜き打ち法であることが好ましい。抜き打ち法は、通常、ロータリー式製造装置を用いて行われる。抜き打ち法は、より詳細には、一対の円筒形の金型の間にカプセル剤皮組成物から得られる2枚の皮膜シートを重ねるように挟み込み、2枚の皮膜シートの間に内容液を注入して、金型により圧切および圧着を同時に行う方法である。 The filling method is not particularly limited, but it is preferably a random punching method. The stamping process is usually performed using rotary manufacturing equipment. More specifically, the punching method involves sandwiching two skin sheets obtained from a capsule shell composition between a pair of cylindrical molds so as to overlap each other, and injecting the liquid content between the two skin sheets. In this method, pressure cutting and crimping are performed simultaneously using a mold.
 なお、本発明に係るカプセル剤皮組成物は、粘度が低く、取り扱い性に優れる。これにより、例えば、カプセル剤の製造時において形成されうるフィルム(湿潤皮膜)の成形性に優れるため充填適正がある(例えば、高速充填が可能となる)、ヒートシール性に優れる等のうち少なくとも1つの効果を奏しうる。
 また、前記カプセル剤皮組成物は、カプセル剤の製造時において形成されるフィルムが好適なゼリー強度および柔軟性を有しうる。このため、カプセル剤の製造時において形成されるフィルムの強度が高い等の効果を奏しうる。
In addition, the capsule shell composition according to the present invention has a low viscosity and is excellent in handleability. As a result, for example, at least one of the following: excellent filling suitability (for example, high-speed filling is possible) due to excellent moldability of a film (wet film) that can be formed during the production of capsules; excellent heat sealability; There are two effects.
In addition, the capsule shell composition may have a jelly strength and flexibility suitable for the film formed during production of the capsule. Therefore, it is possible to obtain effects such as high strength of the film formed during production of the capsule.
 [乾燥工程]
 乾燥工程は、得られた充填物を乾燥する工程である。得られた充填物は、内容液が湿潤皮膜中に充填された構成を有する。乾燥工程において、主に湿潤皮膜が含む水分を除去することで、カプセル皮膜とすることができる。
[Drying process]
A drying process is a process of drying the obtained filling. The resulting filling has a structure in which the content liquid is filled in the wet film. In the drying process, the capsule shell can be obtained by removing mainly the moisture contained in the wet coating.
 乾燥時の温度および相対湿度は、特に制限されないが、温度25~45℃、相対湿度30%RH以下の環境で行われる。 Although the temperature and relative humidity during drying are not particularly limited, it is performed in an environment with a temperature of 25-45°C and a relative humidity of 30% RH or less.
 乾燥工程は、カプセル皮膜の含水率が15%を下回るまで行うことが好ましい。 The drying process is preferably carried out until the water content of the capsule shell falls below 15%.
 以下、実施例を挙げて本発明を具体的に説明するが、本発明はこれらに限定されるものではない。 The present invention will be specifically described below with reference to examples, but the present invention is not limited to these.
 [実施例1]
 澱粉(粘度:46±5mPa・s)と、イオタカラギーナン(粘度:2,600±800mPa・s)と、ガム類であるアラビアガム(粘度:260±80mPa・s)と、可塑剤であるグリセリンと、を表1に記載の配合比で水に混合し、得られる懸濁液を、90℃以上、3時間加温下で撹拌して溶解させることで、カプセル剤皮組成物を製造した。
[Example 1]
Starch (viscosity: 46 ± 5 mPa s), iota carrageenan (viscosity: 2,600 ± 800 mPa s), gum arabic gum (viscosity: 260 ± 80 mPa s), and glycerin as a plasticizer , was mixed with water at the compounding ratio shown in Table 1, and the resulting suspension was stirred and dissolved under heating at 90°C or higher for 3 hours to prepare a capsule shell composition.
 なお、澱粉類の粘度、イオタカラギーナンの粘度、およびガム類の粘度は、以下の方法で測定した。 The viscosity of starches, the viscosity of iota carrageenan, and the viscosity of gums were measured by the following methods.
 (澱粉類の粘度)
 No.12規格瓶に、澱粉類15g、精製水135gを加え、混合し、澱粉類を十分に分散させた後、95℃の湯浴中で90分加熱した。その際、最初の30分は10分おきに、その後は30分おきに撹拌した。撹拌にはスパテルやガラス棒やこれらに準ずるものを用いた。
 その後、糊液が70℃になるまで冷まし、粘度測定を行った。粘度は、得られた10%糊液を用いて、B型粘度計(Brookfield社製 DV-E、液温70℃、ローターNo.2、60rpmで1分間回転させた後の値)で計測した。なお、本実施例では、澱粉類の粘度は、3回測定し、その平均値±SD(標準偏差)として記載した。
(Viscosity of starches)
No. 15 g of starches and 135 g of purified water were added to a 12 standard bottle and mixed to sufficiently disperse the starches, followed by heating in a hot water bath at 95° C. for 90 minutes. At that time, the mixture was stirred every 10 minutes for the first 30 minutes and then every 30 minutes. A spatula, a glass rod, or the like was used for stirring.
After that, the paste liquid was cooled to 70° C., and the viscosity was measured. The viscosity was measured using the obtained 10% paste liquid with a Brookfield viscometer (DV-E manufactured by Brookfield, liquid temperature 70°C, rotor No. 2, value after rotating at 60 rpm for 1 minute). . In addition, in this example, the viscosity of starches was measured 3 times, and was described as the average ±SD (standard deviation).
 (イオタカラギーナンの粘度)
 No.12規格瓶に、イオタカラギーナン5g、グリセリン12gを加え、スパテルでよく混合した後、精製水103gを加え、よく混合した。作製した混合液は、95℃の湯浴中で90分間加熱した。その際、最初の30分は10分おきに、その後は30分おきに撹拌した。
 その後、混合液が70℃になるまで冷まし、粘度測定を行った。粘度は、得られた4%混合液を用いて、B型粘度計(Brookfield社製 DV-E、液温70℃、ローターNo.3、12rpmで1分間回転させた後の値)で計測した。なお、本実施例では、イオタカラギーナンの粘度は、3回測定し、その平均値±SD(標準偏差)として記載した。
(Viscosity of iota carrageenan)
No. After adding 5 g of iota carrageenan and 12 g of glycerin to a 12 standard bottle and mixing well with a spatula, 103 g of purified water was added and mixed well. The prepared mixture was heated in a hot water bath at 95° C. for 90 minutes. At that time, the mixture was stirred every 10 minutes for the first 30 minutes and then every 30 minutes.
After that, the mixed liquid was cooled to 70° C., and the viscosity was measured. The viscosity was measured with a Brookfield viscometer (Brookfield DV-E, liquid temperature 70° C., rotor No. 3, value after rotating at 12 rpm for 1 minute) using the obtained 4% mixed solution. . In this example, the viscosity of iota carrageenan was measured 3 times and expressed as the average ±SD (standard deviation).
 (ガム類の粘度)
 ビーカーに、ガム類25g、精製水75gを入れ、撹拌機でよく混合した。作製した混合液をNo.12規格瓶に移し、混合液を25℃に調整した後、粘度を測定した。
 粘度は、得られた25%混合液を用いて、B型粘度計(Brookfield社製 DV-E、液温25℃、ローターNo.2、60rpmで1分間回転させた後の値)で計測した。なお、本実施例では、ガム類の粘度は、3回測定し、その平均値±SD(標準偏差)として記載した。
(Viscosity of gums)
25 g of gums and 75 g of purified water were placed in a beaker and mixed well with a stirrer. The prepared mixed solution is No. After transferring to a 12 standard bottle and adjusting the mixture to 25° C., the viscosity was measured.
The viscosity was measured with a Brookfield viscometer (Brookfield DV-E, liquid temperature 25° C., rotor No. 2, value after rotating at 60 rpm for 1 minute) using the obtained 25% mixture. . In addition, in this example, the viscosity of gums was measured 3 times, and was described as the average value±SD (standard deviation).
 [実施例2~15、比較例1~6]
 表1および表2に記載の配合比に変更したことを除いては、実施例1と同様の方法で、カプセル剤皮組成物を製造した。
[Examples 2 to 15, Comparative Examples 1 to 6]
A capsule shell composition was produced in the same manner as in Example 1, except that the compounding ratios shown in Tables 1 and 2 were changed.
 なお、使用した原料は以下のとおりである。 The raw materials used are as follows.
 (澱粉類)
 澱粉分解物(デキストロース当量(D.E.)=2~5)(粘度:15m±5mPa・s)
 澱粉分解物(デキストロース当量(D.E.)=10~12)(粘度:13m±5mPa・s)
 ヒドロキシプロピル化澱粉(粘度:34m±5mPa・s、エーテル化度:7%以下)
 なお、上記澱粉類の粘度は、実施例1の澱粉類の粘度の測定方法と同様の方法で測定した。また、エーテル化度は、食添公文書(ヒドロキシプロピル化デンプン)に従い測定した。
(starches)
Starch degradation product (dextrose equivalent (DE) = 2 to 5) (viscosity: 15 m ± 5 mPa s)
Starch degradation product (dextrose equivalent (DE) = 10 to 12) (viscosity: 13 m ± 5 mPa s)
Hydroxypropylated starch (viscosity: 34 m±5 mPa s, degree of etherification: 7% or less)
The viscosity of the starches was measured by the same method as the method for measuring the viscosity of the starches in Example 1. In addition, the degree of etherification was measured in accordance with the Japanese Food Code (Hydroxypropylated Starch).
 (ガム類)
 グァーガムは、ユニテックフーズ株式会社製、ジェランガムは住友ファーマフード&ケミカル株式会社製の市販品をそれぞれ用いた。
(Gums)
Guar gum was manufactured by Unitech Foods Co., Ltd., and gellan gum was manufactured by Sumitomo Pharma Food & Chemical Co., Ltd., respectively.
 (アルギン酸エステル)
 株式会社キミカ製の市販品を用いた。
(alginic acid ester)
A commercially available product manufactured by Kimika Co., Ltd. was used.
 (添加剤)
 プルランは、株式会社林原製の市販品を用いた。
 リン酸水素二ナトリウムは、太平化学産業株式会社製の市販品を用いた。
(Additive)
A commercial product manufactured by Hayashibara Co., Ltd. was used as pullulan.
As disodium hydrogen phosphate, a commercially available product manufactured by Taihei Kagaku Sangyo Co., Ltd. was used.
Figure JPOXMLDOC01-appb-T000002
Figure JPOXMLDOC01-appb-T000002
Figure JPOXMLDOC01-appb-T000003
Figure JPOXMLDOC01-appb-T000003
 [評価]
 実施例1~15、比較例1~6で製造したカプセル剤皮組成物について、粘度を評価した。
 また、前記カプセル剤皮組成物から形成された湿潤皮膜について、ゼリー強度、柔軟性、および充填適正を評価した。
 さらに、前記カプセル剤皮組成物を用いて製造した軟カプセル剤について、硬度、ブロッキング耐性、外観、および崩壊性を評価した。
[evaluation]
Viscosity was evaluated for the capsule shell compositions produced in Examples 1-15 and Comparative Examples 1-6.
Also, the wet film formed from the capsule shell composition was evaluated for jelly strength, flexibility, and filling suitability.
Furthermore, hardness, blocking resistance, appearance, and disintegrability were evaluated for soft capsules produced using the capsule shell composition.
 1.カプセル剤組成物
 (粘度)
 実施例1~15、比較例1~6で製造したカプセル剤皮組成物の粘度を、B型粘度計(東機産業株式会社製 TVB-15、液温95℃、ローターNo.H7、12rpmで1分間回転させた後の値)で計測した。なお、本実施例では、カプセル剤皮組成物の粘度は、3回測定し、その平均値±SD(標準偏差)として記載した。
1. Capsule composition (viscosity)
The viscosities of the capsule shell compositions produced in Examples 1 to 15 and Comparative Examples 1 to 6 were measured using a Brookfield viscometer (TVB-15 manufactured by Toki Sangyo Co., Ltd., liquid temperature 95° C., rotor No. H7, 12 rpm. value after rotating for 1 minute). In addition, in this example, the viscosity of the capsule shell composition was measured three times, and was described as the mean ± SD (standard deviation).
 2.湿潤皮膜
 (ゼリー強度および柔軟性)
 実施例1~15、比較例1~6で製造したカプセル剤皮組成物150gをNo.12規格瓶に入れ、一晩風乾し、サンプルとした。このサンプルを用いてレオメーター(サン科学株式会社製 CR_3000EX_L、アダプターNo.2 φ10mm)を用いてサンプルに荷重をかけて破断するまでのゼリー強度(最大荷重N)および柔軟性(破断距離mm)を測定した。なお、本実施例では、ゼリー強度および柔軟性は、3回測定し、その平均値±SD(標準偏差)として記載した。
2. Wet film (jelly strength and flexibility)
150 g of the capsule shell compositions produced in Examples 1 to 15 and Comparative Examples 1 to 6 were applied to No. It was placed in a 12 standard bottle, air-dried overnight, and used as a sample. Using this sample, a rheometer (CR_3000EX_L manufactured by Sun Science Co., Ltd., adapter No. 2, φ10 mm) was used to measure the jelly strength (maximum load N) and flexibility (breaking distance mm) until the sample was broken by applying a load. It was measured. In addition, in this example, the jelly strength and flexibility were measured three times and described as the mean ± SD (standard deviation).
 (充填適正)
 実施例1~15、比較例1~6で製造したカプセル剤皮組成物を、平滑な金属板上に展延し、乾燥しないように密閉した状態で、室温(22±3℃)、15分間冷却し、ゲル化させて湿潤皮膜(厚さ:0.7mm)を得た。得られた湿潤皮膜のべたつきやカプセル化の可能性を5名の評価者が以下の基準に従って評価し、その平均を評価結果とした。
(Proper filling)
The capsule shell compositions produced in Examples 1 to 15 and Comparative Examples 1 to 6 were spread on a smooth metal plate, sealed to prevent drying, and left at room temperature (22±3° C.) for 15 minutes. It was cooled and gelled to give a wet film (thickness: 0.7 mm). Five evaluators evaluated the stickiness of the resulting wet film and the possibility of encapsulation according to the following criteria, and the average was used as the evaluation result.
 A:良好
 B:若干悪い
 C:悪い
 D:カプセル化不可
A: Good B: Slightly bad C: Poor D: No encapsulation
 3.軟カプセル剤
 (軟カプセル剤の作製)
 実施例1~15、比較例1~6で製造したカプセル剤皮組成物を、ロータリーダイ式カプセル充填機を用いて、中鎖脂肪酸トリグリセリドを内容物として充填し、フットボール型の湿潤カプセルを得た。
 得られた湿潤カプセルを、40±2℃、20%未満の湿度に設定した乾燥機内で乾燥して軟カプセル剤を作製した。なお、乾燥後の軟カプセル剤のカプセル皮膜の含水量は10±1重量%に設定した。
 ここで、含水量は、以下の方法で算出した。すなわち、日本薬局方の乾燥減量試験法に基づき、予め乾燥させておいた秤量瓶に作製した軟カプセル剤のカプセル皮膜0.5gを正確に量り、110℃で2時間乾燥するときの乾燥減量をもとに軟カプセル剤の含水量を算出した。なお、乾燥処理で軟カプセル剤中に含まれる水分はすべて蒸発することを仮定して、下記式で計算した。
3. Soft capsules (production of soft capsules)
The capsule shell compositions produced in Examples 1 to 15 and Comparative Examples 1 to 6 were filled with medium-chain fatty acid triglycerides using a rotary die capsule filling machine to obtain football-shaped wet capsules. .
The resulting wet capsules were dried in a dryer set at 40±2° C. and a humidity of less than 20% to produce soft capsules. The moisture content of the capsule shell of the soft capsule after drying was set to 10±1% by weight.
Here, the water content was calculated by the following method. That is, based on the loss-on-drying test method of the Japanese Pharmacopoeia, accurately weigh 0.5 g of the capsule shell of the soft capsule prepared in a pre-dried weighing bottle, and dry it at 110 ° C. for 2 hours. Based on this, the water content of the soft capsule was calculated. In addition, it was calculated by the following formula, assuming that all the moisture contained in the soft capsule is evaporated by the drying process.
 乾燥減量/試料の重量 × 100=含水量(%) Loss on drying/weight of sample x 100 = water content (%)
 (硬度)
 上記で作製した軟カプセル剤の硬度について、大岩薬品機械株式会社製モンサント型錠剤硬度計(B型30Kg)208-0219-Bを用いて評価した。具体的には、前記錠剤硬度計を用いて軟カプセル剤に圧力をかけ、軟カプセル剤が割れる際にかかっていた荷重(硬度)を測定した。なお、本実施例では、硬度は3回測定し、その平均値±SD(標準偏差)として記載した。
(hardness)
The hardness of the soft capsule prepared above was evaluated using a Monsanto type tablet hardness tester (B type 30 kg) 208-0219-B manufactured by Ohiwa Pharmaceutical Machinery Co., Ltd. Specifically, pressure was applied to the soft capsule using the tablet hardness tester, and the load (hardness) applied when the soft capsule was broken was measured. In this example, the hardness was measured three times, and the average value ± SD (standard deviation) was described.
 (ブロッキング耐性)
 上記で作製した軟カプセル剤20個を、No.6規格瓶に入れ、内密栓・金属キャップをした状態にて、60℃の恒温槽内で3日間静置保管した。その後、瓶を取り出し、室温(22±3℃)に戻した。
(blocking resistance)
20 soft capsules prepared above were placed in a No. It was placed in a 6 standard bottle, sealed with a metal cap, and stored in a constant temperature bath at 60°C for 3 days. The bottle was then removed and allowed to return to room temperature (22±3° C.).
 瓶の内密栓・金属キャップを取り外し、以下のA~Eの条件をAから初めて順に操作し、20個の軟カプセル剤すべてが瓶の中から落下した時点の条件を評価結果とした。瓶表面に付着した軟カプセル剤が低い衝撃で落下する(剥離する)場合、ブロッキング耐性が高い、すなわち、軟カプセル剤表面にべとつきが少なく、軟カプセル剤どうしが付着しにくいといえる。  The inner stopper and metal cap of the bottle were removed, and the following conditions A to E were operated in order starting from A, and the evaluation result was the condition when all 20 soft capsules fell out of the bottle. When the soft capsules adhering to the bottle surface fall (peel off) with a low impact, it can be said that the blocking resistance is high, that is, the surface of the soft capsules is less sticky and the soft capsules are less likely to adhere to each other.
 A:逆さに置く
 B:1cmから逆さに落とす
 C:3cmから逆さに落とす
 D:5cmから逆さに落とす
 E:逆さにして叩きつける
A: Place it upside down B: Drop it upside down from 1cm C: Drop it upside down from 3cm D: Drop it upside down from 5cm E: Hit it upside down
 (外観)
 上記で作製した軟カプセル剤の外観を目視で観察し、軟カプセル剤の透明性および艶を5名の評価者が評価し、その平均を評価結果とした。この際、前記評価は、比較例2のカプセル剤皮組成物から得られた軟カプセル剤の外観を5.0としたとき、1~10の10段階で評価した。
(exterior)
The appearance of the soft capsules prepared above was visually observed, and the transparency and luster of the soft capsules were evaluated by five evaluators, and the average was used as the evaluation result. At this time, the evaluation was made on a 10-point scale from 1 to 10, with the external appearance of the soft capsule obtained from the capsule shell composition of Comparative Example 2 being 5.0.
 (崩壊性)
 上記で作製した軟カプセル剤の崩壊性は、日本薬局方の崩壊試験法に基づいて実施した。この際、試験液には水を用い、6個の軟カプセル剤が20分以内に崩壊するかを評価し、崩壊する場合は「○」と、崩壊しない場合は「×」とした。なお、「崩壊」とは、試料の残留物をガラス管内に全く認めないか、または認めても明らかに原形をとどめない軟質の物質の状態であるとき、あるいはカプセル皮膜の断片となった状態であるときを意味する。
(Collapsible)
The disintegration property of the soft capsule prepared above was performed based on the disintegration test method of the Japanese Pharmacopoeia. At this time, water was used as the test liquid, and whether or not the 6 soft capsules disintegrated within 20 minutes was evaluated. "Disintegration" means that no residue of the sample is found in the glass tube, or that even if it is found, it is in a state of a soft substance that clearly does not retain its original shape, or that it is in a state of fragmentation of the capsule shell. It means when
 上述の評価結果を下記表3に示す。なお、表3中、「-」は未評価であることを示す。 The above evaluation results are shown in Table 3 below. In Table 3, "-" indicates unevaluated.
Figure JPOXMLDOC01-appb-T000004
Figure JPOXMLDOC01-appb-T000004
 表3の結果から、実施例1~15のカプセル剤皮組成物は、粘度が低いことが分かった。また、カプセル剤皮組成物の粘度が低いものの、湿潤皮膜のゼリー強度および柔軟性は高かった。このため、充填適正が良好であり、例えば、高速充填が可能となると考えられる。また、軟カプセル剤の硬度は高かった。その他、軟カプセル剤は、ブロッキング耐性が高く、外観が良好であり、崩壊性にも優れていることが分かった。  From the results in Table 3, it was found that the capsule shell compositions of Examples 1-15 had low viscosities. Also, although the viscosity of the capsule shell composition was low, the jelly strength and flexibility of the wet coating were high. For this reason, it is considered that filling suitability is good and, for example, high-speed filling becomes possible. Also, the hardness of the soft capsule was high. In addition, the soft capsules were found to have high blocking resistance, good appearance, and excellent disintegration properties. 

Claims (17)

  1.  澱粉類、イオタカラギーナン、およびガム類を含む、カプセル剤皮組成物であって、
     前記イオタカラギーナンの含有量が、前記カプセル剤皮組成物100質量%に対して、2質量%以上であり、
     前記ガム類の含有量が、前記カプセル剤皮組成物100質量%に対して、0.3~14質量%である、カプセル剤皮組成物。
    A capsule shell composition comprising starches, iota carrageenan, and gums,
    The content of the iota carrageenan is 2% by mass or more with respect to 100% by mass of the capsule shell composition,
    A capsule shell composition, wherein the gum content is 0.3 to 14% by mass with respect to 100% by mass of the capsule shell composition.
  2.  ゼラチンを含まない、請求項1に記載のカプセル剤皮組成物。 The capsule shell composition according to claim 1, which does not contain gelatin.
  3.  リン酸塩緩衝剤を含まない、請求項1に記載のカプセル剤皮組成物。 The capsule shell composition according to claim 1, which does not contain a phosphate buffer.
  4.  前記ガム類が、アラビアガム、グァーガム、ローカストビーンガム、ジェランガム、キサンタンガム、およびタマリンドガムからなる群から選択される1種以上である、請求項1に記載のカプセル剤皮組成物。 The capsule shell composition according to claim 1, wherein the gums are one or more selected from the group consisting of gum arabic, guar gum, locust bean gum, gellan gum, xanthan gum, and tamarind gum.
  5.  イオタカラギーナンに対する澱粉類の含有量比(澱粉類の含有量(質量%)/イオタカラギーナンの含有量(質量%))が、1.2~10であり、
     ガム類に対する澱粉類の含有量比(澱粉類の含有量(質量%)/ガム類の含有量(質量%))が、1~50であり、
     ガム類に対するイオタカラギーナンの含有量比(イオタカラギーナンの含有量(質量%)/ガム類の含有量(質量%))が、0.5~15である、請求項1に記載のカプセル剤皮組成物。
    The content ratio of starches to iota carrageenan (starch content (mass%) / iota carrageenan content (mass%)) is 1.2 to 10,
    The content ratio of starches to gums (starch content (mass%) / gum content (mass%)) is 1 to 50,
    The capsule shell composition according to claim 1, wherein the content ratio of iota-carrageenan to gums (iota-carrageenan content (mass%)/gums content (mass%)) is 0.5 to 15. thing.
  6.  前記澱粉類の含有量が、カプセル剤皮組成物100質量%に対して、10~30質量%であり、
     前記イオタカラギーナンの含有量が、前記カプセル剤皮組成物100質量%に対して、2~20質量%である、請求項1に記載のカプセル剤皮組成物。
    The starch content is 10 to 30% by mass with respect to 100% by mass of the capsule shell composition,
    2. The capsule shell composition according to claim 1, wherein the content of said iota carrageenan is 2 to 20 mass % with respect to 100 mass % of said capsule shell composition.
  7.  アルギン酸エステルをさらに含む、請求項1に記載のカプセル剤皮組成物。 The capsule shell composition according to claim 1, further comprising alginate.
  8.  可塑剤をさらに含む、請求項1に記載のカプセル剤皮組成物。 The capsule shell composition according to claim 1, further comprising a plasticizer.
  9.  前記澱粉類が、天然澱粉および加工澱粉からなる群から選択される少なくとも1種を含む、請求項1に記載のカプセル剤皮組成物。 The capsule shell composition according to claim 1, wherein the starch contains at least one selected from the group consisting of natural starch and modified starch.
  10.  内容物と、カプセル皮膜と、を含むカプセル剤であって、
     前記カプセル皮膜が、請求項1~9のいずれか1項に記載のカプセル剤皮組成物を用いて形成される、カプセル剤。
    A capsule containing contents and a capsule shell,
    A capsule, wherein the capsule shell is formed using the capsule shell composition according to any one of claims 1 to 9.
  11.  軟カプセル剤である、請求項10に記載のカプセル剤。 The capsule according to claim 10, which is a soft capsule.
  12.  前記カプセル皮膜中のイオタカラギーナンに対する澱粉類の含有量比(澱粉類の含有量(質量%)/イオタカラギーナンの含有量(質量%))が、1.2~10であり、
     前記カプセル皮膜中のガム類に対する澱粉類の含有量比(澱粉類の含有量(質量%)/ガム類の含有量(質量%))が、1~50であり、
     前記カプセル皮膜中のガム類に対するイオタカラギーナンの含有量比(イオタカラギーナンの含有量(質量%)/ガム類の含有量(質量%))が、0.5~15である、請求項10に記載のカプセル剤。
    The content ratio of starch to iota carrageenan in the capsule shell (starch content (mass%) / iota carrageenan content (mass%)) is 1.2 to 10,
    The content ratio of starches to gums in the capsule shell (starch content (mass%) / gum content (mass%)) is 1 to 50,
    The content ratio of iota-carrageenan to gums in the capsule shell (iota-carrageenan content (% by mass)/gum content (% by mass)) is 0.5 to 15 according to claim 10. capsules.
  13.  内容物と、
     澱粉類、イオタカラギーナン、およびガム類を含む、カプセル皮膜と、
    を含み、
     硬度が15kg以上である、カプセル剤。
    the contents;
    a capsule shell comprising starches, iota carrageenan, and gums;
    including
    A capsule having a hardness of 15 kg or more.
  14.  前記カプセル皮膜が、ゼラチンを含まない、請求項13に記載のカプセル剤。 The capsule according to claim 13, wherein the capsule shell does not contain gelatin.
  15.  前記カプセル皮膜が、リン酸塩緩衝剤を含まない、請求項13に記載のカプセル剤。 The capsule according to claim 13, wherein the capsule shell does not contain a phosphate buffer.
  16.  軟カプセル剤である、請求項13に記載のカプセル剤。 The capsule according to claim 13, which is a soft capsule.
  17.  前記カプセル皮膜中のイオタカラギーナンに対する澱粉類の含有量比(澱粉類の含有量(質量%)/イオタカラギーナンの含有量(質量%))が、1.2~10であり、
     前記カプセル皮膜中のガム類に対する澱粉類の含有量比(澱粉類の含有量(質量%)/ガム類の含有量(質量%))が、1~50であり、
     前記カプセル皮膜中のガム類に対するイオタカラギーナンの含有量比(イオタカラギーナンの含有量(質量%)/ガム類の含有量(質量%))が、0.5~15である、請求項13に記載のカプセル剤。 
    The content ratio of starch to iota carrageenan in the capsule shell (starch content (mass%) / iota carrageenan content (mass%)) is 1.2 to 10,
    The content ratio of starches to gums in the capsule shell (starch content (mass%) / gum content (mass%)) is 1 to 50,
    The content ratio of iota carrageenan to gums in the capsule shell (iota carrageenan content (% by mass)/gum content (% by mass)) is 0.5 to 15 according to claim 13. capsules.
PCT/JP2022/029330 2021-07-30 2022-07-29 Capsule shell composition and capsule obtained using same WO2023008567A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023538643A JPWO2023008567A1 (en) 2021-07-30 2022-07-29

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2021-125530 2021-07-30
JP2021125530 2021-07-30

Publications (1)

Publication Number Publication Date
WO2023008567A1 true WO2023008567A1 (en) 2023-02-02

Family

ID=85086932

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2022/029330 WO2023008567A1 (en) 2021-07-30 2022-07-29 Capsule shell composition and capsule obtained using same

Country Status (2)

Country Link
JP (1) JPWO2023008567A1 (en)
WO (1) WO2023008567A1 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006526057A (en) * 2003-04-14 2006-11-16 エフ エム シー コーポレーション Uniform and thermoreversible low viscosity polymannan gum film and soft capsule made therefrom
JP2021100917A (en) * 2019-12-24 2021-07-08 中日本カプセル 株式会社 Soft capsule film, soft capsule, and production method of soft capsule

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006526057A (en) * 2003-04-14 2006-11-16 エフ エム シー コーポレーション Uniform and thermoreversible low viscosity polymannan gum film and soft capsule made therefrom
JP2007525551A (en) * 2003-04-14 2007-09-06 エフ エム シー コーポレーション Uniform and thermoreversible gel film containing kappa-2 carrageenan and soft capsule made therefrom
JP2007528357A (en) * 2003-04-14 2007-10-11 エフ エム シー コーポレーション Method for producing a gel film
JP2021100917A (en) * 2019-12-24 2021-07-08 中日本カプセル 株式会社 Soft capsule film, soft capsule, and production method of soft capsule

Also Published As

Publication number Publication date
JPWO2023008567A1 (en) 2023-02-02

Similar Documents

Publication Publication Date Title
Kulkarni Vishakha et al. Natural polymers–A comprehensive review
EP1117736B2 (en) Modified starch film compositions
AU2010358565B2 (en) Film-forming composition for soft capsules
JP2007525551A (en) Uniform and thermoreversible gel film containing kappa-2 carrageenan and soft capsule made therefrom
US20070034827A1 (en) Blends of gelling and non-gelling starches with gellan gums and plasticizer
CN1870901A (en) Gelatin-free, isomaltulose-containing soft caramel
US20070128267A1 (en) Blends of gelling and non-gelling starches with gellan gums and plasticizer
JP2023536023A (en) soft capsule capsule shell and soft capsule
US10493036B2 (en) Enteric capsule
CN107847454A (en) Film-forming composition based on starch material and the product by its acquisition
CN113768137A (en) Starch film-forming composition and method for preparing capsule shell by using same
KR20130065651A (en) Lozenges of erythritol and isomalt
JP5334727B2 (en) Soft capsule manufacturing method
KR101675438B1 (en) Composition for preparing soft capsule shell
KR101445334B1 (en) Vegetable Soft Capsule Composition without Chemical Metal Salts
WO2023008567A1 (en) Capsule shell composition and capsule obtained using same
JP5539621B2 (en) Capsule skin composition and capsule
JP6133168B2 (en) Capsule film composition
JP2017178822A (en) tablet
CN112494453B (en) Agar/maltodextrin slow-release capsule and preparation method thereof
JP6216088B1 (en) Oral sustained release composition and method for producing the same
JP2003299714A (en) Film composition of soft capsule
JP4220159B2 (en) Capsule
JP2003125714A (en) Capsule base material and capsule made from the base material, and method for producing the capsule base material
Verma et al. A Review on the polymers for vegetarian soft gel capsule films

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22849627

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2023538643

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE